var title_f9_21_9552="Nucleated RBC in AIHA";
var content_f9_21_9552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F50601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F50601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral smear in severe autoimmune hemolytic anemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear from a patient with Coombs positive autoimmune hemolytic anemia. The smear shows the presence of many spherocytes (red arrows), one nucleated red blood cell (blue arrow), and a number of larger polychromatophilic red cells (black arrows), representing a reticulocytosis in response to the anemia.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carola von Kapff, SH (ASCP).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9552=[""].join("\n");
var outline_f9_21_9552=null;
var title_f9_21_9553="Piebaldism";
var content_f9_21_9553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58857&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Piebaldism",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patchy areas of depigmentation in a child with piebaldism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9553=[""].join("\n");
var outline_f9_21_9553=null;
var title_f9_21_9554="DISH radiograph thoracic spine";
var content_f9_21_9554=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F68698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F68698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiographs of thoracic spine in diffuse idiopathic skeletal hyperostosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 445px; height: 427px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ossification of the anterior longitudinal ligament, similar in appearance to flowing candle wax (arrow), is seen in the lateral view of the thoracic spine (left radiograph) in a patient with diffuse idiopathic skeletal hyperostosis (DISH). The changes are predominantly on the right side, particularly in mid-thoracic spine (anteroposterior view, right radiograph). There is both complete and incomplete bridging of the spurs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John Esdaile, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9554=[""].join("\n");
var outline_f9_21_9554=null;
var title_f9_21_9555="Extensive lactating infection";
var content_f9_21_9555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F76043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F76043&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Extensive lactating infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Extensive lactating infection after incision and drainage of two separate abscesses.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9555=[""].join("\n");
var outline_f9_21_9555=null;
var title_f9_21_9556="Chenodeoxycholic acid (chenodiol): Patient drug information";
var content_f9_21_9556=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chenodeoxycholic acid (chenodiol): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33076?source=see_link\">",
"     see \"Chenodeoxycholic acid (chenodiol): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10484405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Chenodal&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10492769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691502",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat gallstones.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10492768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2847139",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chenodiol or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10492773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697183",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have biliary tract problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696830",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids with this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2770240",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10492774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals and good mouth care may help. Older children may suck hard, sugar-free candy.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10492776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10492771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10492772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10492777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10492778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15547 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9556=[""].join("\n");
var outline_f9_21_9556=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10484405\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492769\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492768\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492773\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492774\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492776\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492771\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492772\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492777\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10492778\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33076?source=related_link\">",
"      Chenodeoxycholic acid (chenodiol): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_21_9557="Vascular supply of the spleen";
var content_f9_21_9557=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 553px\">",
"   <div class=\"ttl\">",
"    Vascular supply of the spleen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 533px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The splenic artery is a branch of the celiac trunk. It traverses along the superior margin of the pancreas toward the spleen branching to form up to six major arteries before entering the spleen. The splenic vein joins the superior mesenteric vein to form the portal vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9557=[""].join("\n");
var outline_f9_21_9557=null;
var title_f9_21_9558="Whole body Langers lines";
var content_f9_21_9558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F57566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F57566&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Whole body Langer's lines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 436px; height: 480px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic drawing of the cleavage (Langer's) lines in the skin. Surgical incisions made in the direction of these lines, which run parallel to the predominant direction of the collagen fiber bundles in the dermis, have less tendency to gape.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Dalley II AF. Clinical Oriented Anatomy, Fourth Edition. Baltimore, Lippincott Williams &amp; Wilkins 1999. Copyright &copy; 1999 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9558=[""].join("\n");
var outline_f9_21_9558=null;
var title_f9_21_9559="Treatment of locally recurrent head and neck cancer";
var content_f9_21_9559=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of locally recurrent head and neck cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/21/9559/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9559/contributors\">",
"     Michael T Milano, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9559/contributors\">",
"     Steven J Chmura, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9559/contributors\">",
"     Daniel J Haraf, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/21/9559/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9559/contributors\">",
"     David M Brizel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/21/9559/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9559/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/21/9559/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Locoregional recurrences are seen in 15 to 50 percent of patients with squamous cell carcinoma of the head and neck, and this a major factor contributing deaths from head and neck cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment options for patients with locally recurrent head and neck cancer will be reviewed here. Recurrent nasopharyngeal cancer and recurrent salivary gland tumors are discussed separately. Other related topics include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=see_link\">",
"       \"Second primary malignancies in patients with head and neck cancers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16280?source=see_link\">",
"       \"Treatment of recurrent and metastatic nasopharyngeal carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11816?source=see_link\">",
"       \"Malignant salivary gland tumors: Treatment of recurrent and metastatic disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"       \"Treatment of metastatic and recurrent head and neck cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Survival is poor for most patients with recurrent disease, and therapeutic options are limited by previous treatment. An important part of the evaluation of patients with recurrent head and neck cancer is distinguishing those who are candidates for aggressive, curative-intent therapies (surgical salvage, reirradiation) from those for whom palliative measures and supportive care are more appropriate.",
"   </p>",
"   <p>",
"    All patients with local or regionally recurrent disease should be evaluated for distant metastases. Systemic therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiotherapy irradiation can be considered for those with distant metastatic disease. Those whose disease is confined to the head and neck may benefit from definitive therapy (surgical salvage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reirradiation).",
"   </p>",
"   <p>",
"    The stage of recurrent disease may identify those patients who are most likely to benefit from aggressive treatment. A combined analysis that included 32 reports from the literature and a case series of 109 cases who underwent salvage surgery stratified outcomes and complication risks by stage of disease at recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with stage I and II recurrent cancer, the two-year recurrence-free survival with salvage surgery was 70 percent; 60 to 85 percent achieved or exceeded presurgical quality of life (QOL); and the surgical complication rate was 6 percent.",
"     </li>",
"     <li>",
"      For patients with stage III recurrent cancer, the two-year recurrence free survival dropped to 30 percent. Significant complications occurred in 30 percent while only 40 percent of patients achieved or exceeded their baseline QOL.",
"     </li>",
"     <li>",
"      For patients with stage IV recurrent cancer, outcomes were poor. Less than one fourth of patients lived recurrence-free for two years; half of patients had a recurrence before five months and died within nine months. Complication rates and QOL were similar to stage III patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The initial disease-free interval also plays an important role in determining treatment approach as patients with disease recurrence within one year of initial treatment have significantly worse survival than patients who recur later [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/6\">",
"     6",
"    </a>",
"    ]. Furthermore, patients with a second primary malignancy rather than a true recurrence may have better prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=see_link\">",
"     \"Second primary malignancies in patients with head and neck cancers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SALVAGE SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Salvage surgery provides the best opportunity, particularly among patients who previously underwent head and neck radiotherapy for long-term survival if the volume and location of recurrent disease are amenable to resection and the patient is medically operable [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/5,8-10\">",
"     5,8-10",
"    </a>",
"    ]. However, the morbidity associated with salvage surgery can be substantial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Open surgical salvage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five-year overall survival rates after salvage surgery generally range from 11 to 39 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/5,11-14\">",
"     5,11-14",
"    </a>",
"    ]. Factors such as site and stage of recurrence, patient age, and disease-free interval have a significant effect on prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/5,15,16\">",
"     5,15,16",
"    </a>",
"    ]. Higher survival rates have been reported for highly selected patient populations; as an example, small, locally recurrent laryngeal cancers have been associated with five-year survival rates of 84 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vast majority of patients who undergo salvage surgery for head and neck cancer were previously treated with radiotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/5\">",
"     5",
"    </a>",
"    ]. In these patients, complication rates can be higher than with surgery in previously untreated patients. A meta-analysis that included data from 1633 patients, reported rates of operative mortality, total complications, and major complications of 5.2 (range 0 to 18), 39 (range 10 to 88), and 27 (range 5 to 48) percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/5\">",
"     5",
"    </a>",
"    ]. Major complications include large salivary fistula, partial or total flap necrosis, pneumonia, carotid rupture, and stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/12\">",
"     12",
"    </a>",
"    ]. Minor complications included wound infections, small salivary fistula, wound dehiscence, and minor flap necrosis.",
"   </p>",
"   <p>",
"    Despite the potential complications, many patients report an improved quality of life (QOL) following surgery. An observational study of 107 patients measured QOL before and after surgery using both the Functional Living Index for Cancer (FLIC), which is a general measure of QOL, and the Performance Status Scale (PSS) for Head and Neck Cancer Patients, which includes subscales that measure normalcy of diet, understandability of speech, and eating in public [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/5\">",
"     5",
"    </a>",
"    ]. After surgery, 51 percent of patients showed improvement in FLIC, with a 16 percent average increase in FLIC score over baseline, achieved over a mean of 4.8 months. The percentage of patients who reached or exceeded their presurgery baseline PSS score for normalcy of diet, understandability of speech, and public eating behavior were 47, 41, and 50 percent with average improvement of 2 to 30 percent over baseline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3466?source=see_link\">",
"     \"Quality of life in head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Much of the data on QOL and complications come from patients treated initially with primary surgery or radiotherapy alone. As more patients are treated with definitive chemoradiation for functional organ preservation, there may be an increased role for surgical salvage. However, prior treatment with chemoradiation may complicate the management of patients who require salvage surgery. The limited data suggest that the number of total complications is increased in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/12,17-19\">",
"     12,17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advances in reconstructive surgery, particularly the use of microvascular free flaps, have allowed more patients to be candidates for salvage surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/5,17,20-23\">",
"     5,17,20-23",
"    </a>",
"    ]. Free flap reconstruction decreases local wound complications by bringing nonirradiated vascularized tissue into the wound; however, this technique prolongs surgeries and creates a donor site wound [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/17,20\">",
"     17,20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Conservative surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;More conservative surgical procedures may offer an alternative for carefully selected patients with localized recurrences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Partial laryngectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carefully selected patients with local recurrence of laryngeal and hypopharyngeal cancers may be candidates for conservative resection with partial laryngectomy rather than total laryngectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/15,24\">",
"     15,24",
"    </a>",
"    ]. As an example, one case series included patients with subglottic extension not greater than 5 mm, cartilage not invaded as determined by computed tomographic (CT) scan, extension to contralateral cord not greater than 3 mm, arytenoids (except vocal process) free of tumor, mobility of vocal cord preserved, and supraglottic extension no further than the lateral sinus of Morgagni. For these patients, partial laryngectomy offered five-year survival compared to total laryngectomy (40 versus 26 percent) and at least some degree of serviceable speech (87.5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Transoral laser microsurgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transoral laser microsurgery (TLM) provides an alternative to open salvage surgery for appropriately selected patients with recurrent laryngeal and oropharyngeal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/25-30\">",
"     25-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, in a series of 114 patients treated with TLM for recurrent laryngeal or pharyngeal cancer, resection with negative margins was achieved in 97 percent of patients, which resulted in a five-year locoregional control and overall survival of 67 and 58 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/30\">",
"     30",
"    </a>",
"    ]. Although temporary tracheostomy and gastrostomy tubes were required in 20 and 28 percent of cases, respectively, only one patient required a tracheostomy and two needed feeding-tubes after treatment. There was a treatment-related mortality rate of 2 percent and the average hospital stay of two days. After treatment, the majority of patients reported normal swallowing and normal communication with minor dysphonia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Prophylactic neck dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of prophylactic neck dissection for patients undergoing surgical salvage is unclear. Some retrospective series of patients who underwent surgical salvage and simultaneous neck dissection report that the risk of occult nodal metastases is low [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. However, others have demonstrated higher rates of occult nodal metastases in some patient groups. As an example, in patients with laryngeal cancer, occult metastases were detected in 20 percent of patients with supraglottic recurrence as well as in those with T3 or higher glottic recurrence (",
"    <a class=\"graphic graphic_table graphicRef66619 \" href=\"UTD.htm?22/14/22766\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bilateral neck dissection is usually performed for patients with recurrent disease in sites associated with high risk of occult nodal metastases, for example, recurrent supraglottic, glottic, or pharyngeal cancer, and with extensive recurrences from other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/5,15,34\">",
"     5,15,34",
"    </a>",
"    ]. Other patients with clinically negative neck nodes undergoing surgical salvage are treated with ipsilateral selective neck dissection or in the case of paranasal sinus or nasal cavity cancer, they may forego neck dissection completely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Postoperative radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The addition of postoperative reirradiation to surgical salvage may improve locoregional control as compared to surgery alone, but a randomized trial showed there was no improvement in overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/35\">",
"     35",
"    </a>",
"    ]. We suggest limiting the routine use of postoperative reirradiation for surgically resected patients with high-risk pathologic features: positive margins, perineural invasion, lymphovascular invasion, and extranodal extension. We do not suggest postoperative reirradiation for patients without high-risk features. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=see_link&amp;anchor=H8#H8\">",
"     \"Reirradiation for locally recurrent head and neck cancer\", section on 'Postoperative Reirradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     REIRRADIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are candidates for aggressive therapy but have tumors not amenable to surgical salvage, reirradiation with or without concurrent chemotherapy may offer long term survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/36\">",
"     36",
"    </a>",
"    ]. Reirradiation for an isolated lymph node recurrence may result in a good response rate but long-term local control is achieved in 10 percent or fewer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Comorbidity and pre-existing organ dysfunction are important prognostic factors influencing the outcome after reirradiation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/39\">",
"     39",
"    </a>",
"    ]. Whether chemotherapy concurrent with radiotherapy can improve upon these outcomes is unknown. Complications associated with reirradiation with or without chemotherapy are significant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reirradiation for locally recurrent head and neck cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=see_link\">",
"     \"Reirradiation for locally recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ISOLATED NECK RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Isolated neck recurrences are uncommon, occurring in 2 to 7 percent of patients who completed initial therapy. Surgical salvage of an isolated neck recurrence is feasible in 30 to 50 percent of patients with isolated neck recurrences, particularly if the relapse develops in a previously irradiated area. Five-year rates of both disease control and survival are about 10 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/37,40-43\">",
"     37,40-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results are worse for patients with recurrent disease in a previously dissected neck because surgical salvage is technically difficult, associated with an increased risk of complications, and more likely to result in residual disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/37,44,45\">",
"     37,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Postoperative treatment with RT is suggested for patients who have not been previously irradiated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/42\">",
"     42",
"    </a>",
"    ]. Salvage neck dissection followed by interstitial brachytherapy may also be considered, especially for patients previously irradiated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiation combined with concurrent chemotherapy in a previously untreated neck or reirradiation with or without concurrent chemotherapy is preferable to surgery if multiple lymph nodes are involved or if there is evidence of extracapsular extension [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9559/abstract/37,38,42\">",
"     37,38,42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=see_link\">",
"     \"Reirradiation for locally recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11288453\">",
"    <span class=\"h1\">",
"     PALLIATIVE CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy is palliative for patients with recurrent head and neck cancer. Because of the toxicity associated with salvage surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiotherapy after prior radiotherapy, patients with poor performance status, recurrent cancer not amenable to salvage therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who choose a less aggressive approach may opt for palliative chemotherapy. &nbsp;At best, objective response rates are 15 to 30 percent, and median survival averages six months. Prior treatment, particularly with radiotherapy, poor performance status, and extensive disease may all reduce response rates and survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=see_link\">",
"     \"Treatment of metastatic and recurrent head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients presenting with locally recurrent head and neck cancer present a therapeutic challenge. Treatment options are limited because of prior therapy, especially radiotherapy, and toxicity and morbidity can be substantial. Nevertheless, selected patients with recurrent disease may achieve long-term survival.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend salvage surgery for patients with recurrent head and neck cancer if the volume and location of recurrent disease are amenable to resection and the patient is medically operable (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Salvage surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest elective bilateral neck dissection only for patients at high risk of occult nodal disease (eg, recurrent supraglottic, glottic, and pharyngeal cancer) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Other patients with clinically negative neck nodes undergoing surgical salvage are treated with ipsilateral selective neck dissection. Patients with paranasal sinus and nasal cavity cancer, with no clinical evidence of lymph node involvement, may forego neck dissection all together. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Salvage surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest postoperative reirradiation for surgically resected patients with high-risk pathologic features (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=see_link&amp;anchor=H8#H8\">",
"       \"Reirradiation for locally recurrent head and neck cancer\", section on 'Postoperative Reirradiation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest reirradiation with concurrent chemotherapy for selected patients with unresectable locally recurrent head and neck cancer (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=see_link&amp;anchor=H15#H15\">",
"       \"Reirradiation for locally recurrent head and neck cancer\", section on 'Reirradiation with concurrent chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest surgical salvage if feasible for an isolated neck recurrence (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Isolated neck recurrence'",
"      </a>",
"      above.) Radiation therapy with concurrent chemotherapy is preferable for multiple neck nodes and extracapsular extension.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/1\">",
"      Bourhis J, Le Ma&icirc;tre A, Baujat B, et al. Individual patients' data meta-analyses in head and neck cancer. Curr Opin Oncol 2007; 19:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/2\">",
"      Brockstein B, Haraf DJ, Rademaker AW, et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience. Ann Oncol 2004; 15:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/3\">",
"      Salama JK, Seiwert TY, Vokes EE. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol 2007; 25:4118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/4\">",
"      Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/5\">",
"      Goodwin WJ Jr. Salvage surgery for patients with recurrent squamous cell carcinoma of the upper aerodigestive tract: when do the ends justify the means? Laryngoscope 2000; 110:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/6\">",
"      Spencer SA, Harris J, Wheeler RH, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck 2008; 30:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/7\">",
"      Spencer SA, Harris J, Wheeler RH, et al. RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys 2001; 51:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/8\">",
"      McLaughlin MP, Parsons JT, Fein DA, et al. Salvage surgery after radiotherapy failure in T1-T2 squamous cell carcinoma of the glottic larynx. Head Neck 1996; 18:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/9\">",
"      Wong LY, Wei WI, Lam LK, Yuen AP. Salvage of recurrent head and neck squamous cell carcinoma after primary curative surgery. Head Neck 2003; 25:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/10\">",
"      Arnold DJ, Goodwin WJ, Weed DT, Civantos FJ. Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck. Semin Radiat Oncol 2004; 14:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/11\">",
"      Parsons JT, Mendenhall WM, Stringer SP, et al. Salvage surgery following radiation failure in squamous cell carcinoma of the supraglottic larynx. Int J Radiat Oncol Biol Phys 1995; 32:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/12\">",
"      Agra IM, Carvalho AL, Pontes E, et al. Postoperative complications after en bloc salvage surgery for head and neck cancer. Arch Otolaryngol Head Neck Surg 2003; 129:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/13\">",
"      Davidson J, Keane T, Brown D, et al. Surgical salvage after radiotherapy for advanced laryngopharyngeal carcinoma. Arch Otolaryngol Head Neck Surg 1997; 123:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/14\">",
"      Kostrzewa JP, Lancaster WP, Iseli TA, et al. Outcomes of salvage surgery with free flap reconstruction for recurrent oral and oropharyngeal cancer. Laryngoscope 2010; 120:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/15\">",
"      Ganly I, Patel SG, Matsuo J, et al. Results of surgical salvage after failure of definitive radiation therapy for early-stage squamous cell carcinoma of the glottic larynx. Arch Otolaryngol Head Neck Surg 2006; 132:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/16\">",
"      Zafereo ME, Hanasono MM, Rosenthal DI, et al. The role of salvage surgery in patients with recurrent squamous cell carcinoma of the oropharynx. Cancer 2009; 115:5723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/17\">",
"      Lee SC, Shores CG, Weissler MC. Salvage surgery after failed primary concomitant chemoradiation. Curr Opin Otolaryngol Head Neck Surg 2008; 16:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/18\">",
"      Young VN, Mangus BD, Bumpous JM. Salvage laryngectomy for failed conservative treatment of laryngeal cancer. Laryngoscope 2008; 118:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/19\">",
"      Richey LM, Shores CG, George J, et al. The effectiveness of salvage surgery after the failure of primary concomitant chemoradiation in head and neck cancer. Otolaryngol Head Neck Surg 2007; 136:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/20\">",
"      Kim AJ, Suh JD, Sercarz JA, et al. Salvage surgery with free flap reconstruction: factors affecting outcome after treatment of recurrent head and neck squamous carcinoma. Laryngoscope 2007; 117:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/21\">",
"      Dubsky PC, Stift A, Rath T, Kornfehl J. Salvage surgery for recurrent carcinoma of the hypopharynx and reconstruction using jejunal free tissue transfer and pectoralis major muscle pedicled flap. Arch Otolaryngol Head Neck Surg 2007; 133:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/22\">",
"      Zou H, Zhang WF, Han QB, Zhao YF. Salvage reconstruction of extensive recurrent oral cancer defects with the pectoralis major myocutaneous flap. J Oral Maxillofac Surg 2007; 65:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/23\">",
"      Head C, Sercarz JA, Abemayor E, et al. Microvascular reconstruction after previous neck dissection. Arch Otolaryngol Head Neck Surg 2002; 128:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/24\">",
"      Marioni G, Marchese-Ragona R, Lucioni M, Staffieri A. Organ-preservation surgery following failed radiotherapy for laryngeal cancer. Evaluation, patient selection, functional outcome and survival. Curr Opin Otolaryngol Head Neck Surg 2008; 16:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/25\">",
"      Steiner W, Vogt P, Ambrosch P, Kron M. Transoral carbon dioxide laser microsurgery for recurrent glottic carcinoma after radiotherapy. Head Neck 2004; 26:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/26\">",
"      Puxeddu R, Piazza C, Mensi MC, et al. Carbon dioxide laser salvage surgery after radiotherapy failure in T1 and T2 glottic carcinoma. Otolaryngol Head Neck Surg 2004; 130:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/27\">",
"      de Gier HH, Knegt PP, de Boer MF, et al. CO2-laser treatment of recurrent glottic carcinoma. Head Neck 2001; 23:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/28\">",
"      Sewnaik A, Meeuwis CA, van der Kwast TH, Kerrebijn JD. Partial laryngectomy for recurrent glottic carcinoma after radiotherapy. Head Neck 2005; 27:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/29\">",
"      Quer M, Le&oacute;n X, Or&uacute;s C, et al. Endoscopic laser surgery in the treatment of radiation failure of early laryngeal carcinoma. Head Neck 2000; 22:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/30\">",
"      Grant DG, Salassa JR, Hinni ML, et al. Transoral laser microsurgery for recurrent laryngeal and pharyngeal cancer. Otolaryngol Head Neck Surg 2008; 138:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/31\">",
"      Dagan R, Morris CG, Kirwan JM, et al. Elective neck dissection during salvage surgery for locally recurrent head and neck squamous cell carcinoma after radiotherapy with elective nodal irradiation. Laryngoscope 2010; 120:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/32\">",
"      Temam S, Koka V, Mamelle G, et al. Treatment of the N0 neck during salvage surgery after radiotherapy of head and neck squamous cell carcinoma. Head Neck 2005; 27:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/33\">",
"      Farrag TY, Lin FR, Cummings CW, et al. Neck management in patients undergoing postradiotherapy salvage laryngeal surgery for recurrent/persistent laryngeal cancer. Laryngoscope 2006; 116:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/34\">",
"      Yao M, Roebuck JC, Holsinger FC, Myers JN. Elective neck dissection during salvage laryngectomy. Am J Otolaryngol 2005; 26:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/35\">",
"      Janot F, de Raucourt D, Benhamou E, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol 2008; 26:5518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/36\">",
"      McDonald MW, Lawson J, Garg MK, et al. ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer. Int J Radiat Oncol Biol Phys 2011; 80:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/37\">",
"      Chopra S, Gupta T, Agarwal JP, et al. Re-irradiation in the management of isolated neck recurrences: current status and recommendations. Radiother Oncol 2006; 81:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/38\">",
"      Emami B, Bignardi M, Spector GJ, et al. Reirradiation of recurrent head and neck cancers. Laryngoscope 1987; 97:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/39\">",
"      Tanvetyanon T, Padhya T, McCaffrey J, et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol 2009; 27:1983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/40\">",
"      Liauw SL, Amdur RJ, Morris CG, et al. Isolated neck recurrence after definitive radiotherapy for node-positive head and neck cancer: salvage in the dissected or undissected neck. Head Neck 2007; 29:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/41\">",
"      Mabanta SR, Mendenhall WM, Stringer SP, Cassisi NJ. Salvage treatment for neck recurrence after irradiation alone for head and neck squamous cell carcinoma with clinically positive neck nodes. Head Neck 1999; 21:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/42\">",
"      Watson JC, Ridge JA. Surgical management of local and regional recurrent head and neck squamous cell carcinoma. Curr Opin Oncol 1998; 10:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/43\">",
"      Jones AS, Tandon S, Helliwell TR, et al. Survival of patients with neck recurrence following radical neck dissection: utility of a second neck dissection? Head Neck 2008; 30:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/44\">",
"      Grandi C, Mingardo M, Guzzo M, et al. Salvage surgery of cervical recurrences after neck dissection or radiotherapy. Head Neck 1993; 15:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/45\">",
"      Kowalski LP. Results of salvage treatment of the neck in patients with oral cancer. Arch Otolaryngol Head Neck Surg 2002; 128:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/46\">",
"      Kupferman ME, Morrison WH, Santillan AA, et al. The role of interstitial brachytherapy with salvage surgery for the management of recurrent head and neck cancers. Cancer 2007; 109:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9559/abstract/47\">",
"      Bollet MA, Lapeyre M, Marchal C, et al. Cervical lymph node relapses of head-and-neck squamous cell carcinoma: is brachytherapy a therapeutic option? Int J Radiat Oncol Biol Phys 2001; 51:1305.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3373 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-211.167.112.17-380DEE3FB3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9559=[""].join("\n");
var outline_f9_21_9559=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SALVAGE SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Open surgical salvage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Conservative surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Partial laryngectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Transoral laser microsurgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Prophylactic neck dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Postoperative radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      REIRRADIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ISOLATED NECK RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11288453\">",
"      PALLIATIVE CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3373\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3373|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/14/22766\" title=\"table 1\">",
"      TNM stage larynx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/34/11816?source=related_link\">",
"      Malignant salivary gland tumors: Treatment of recurrent and metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3466?source=related_link\">",
"      Quality of life in head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38265?source=related_link\">",
"      Reirradiation for locally recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=related_link\">",
"      Second primary malignancies in patients with head and neck cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/25/40345?source=related_link\">",
"      Treatment of metastatic and recurrent head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16280?source=related_link\">",
"      Treatment of recurrent and metastatic nasopharyngeal carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_21_9560="Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging";
var content_f9_21_9560=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medullary thyroid cancer: Clinical manifestations, diagnosis, and staging",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/21/9560/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9560/contributors\">",
"     R Michael Tuttle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/21/9560/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9560/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/21/9560/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9560/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/21/9560/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medullary thyroid cancer (MTC) is a neuroendocrine tumor of the parafollicular or C cells of the thyroid gland. MTC accounts for approximately 4 percent of thyroid carcinomas. The production of calcitonin is a characteristic feature of this tumor. The C cells originate from the embryonic neural crest; as a result, medullary carcinomas often have the clinical and histologic features of other neuroendocrine tumors such as carcinoid and islet-cell tumors.",
"   </p>",
"   <p>",
"    Most medullary thyroid carcinomas are sporadic. However, some are familial as part of the multiple endocrine neoplasia type 2 (MEN2) syndrome. The clinical manifestations, diagnosis, evaluation, and clinical staging of medullary thyroid cancer will be covered in this topic review. Treatment of this disorder is discussed separately. MEN2 is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38263?source=see_link\">",
"     \"Medullary thyroid cancer: Treatment and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link\">",
"     \"Approach to therapy in multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1589428\">",
"    <span class=\"h2\">",
"     Sporadic MTC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sporadic MTC accounts for about 80 percent of all cases of the disease (",
"    <a class=\"graphic graphic_table graphicRef85653 \" href=\"UTD.htm?23/5/23643\">",
"     table 1",
"    </a>",
"    ). The typical age of presentation is in the fifth or sixth decade, and there may be a slight female preponderance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common presentation of sporadic MTC is that of a solitary thyroid nodule, which occurs in 75 to 95 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The C cells are predominantly located in the upper portion of each thyroid lobe; thus, most tumors are located in this region. In most patients with MTC, the disease has already metastasized at the time of diagnosis. Approximately 50 percent of patients have clinically detectable cervical lymph node involvement, up to 15 percent have symptoms of upper aerodigestive tract compression or invasion such as dysphagia or hoarseness, and about 5 percent have distant metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/5\">",
"     5",
"    </a>",
"    ]. Distant metastases may occur in the liver, lung, bones, and less often, brain and skin. Nodal metastases are more common in patients with multifocal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/6\">",
"     6",
"    </a>",
"    ]. However, as calcitonin screening results in the identification of more \"micro\" medullary cancers, the number of patients with metastases at presentation appears to be decreasing. As an example, in a European surgical series, 61 percent of the medullary cancers were under 10 mm, and only 11 percent had cervical nodal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Serum calcitonin concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic symptoms may occur due to hormonal secretion by the tumor. Tumor secretion of calcitonin, calcitonin-gene related peptide, or other substances can cause diarrhea or facial flushing in patients with advanced disease. In addition, occasional tumors secrete corticotropin (ACTH), causing ectopic Cushing's syndrome.",
"   </p>",
"   <p>",
"    Basal serum calcitonin concentrations usually correlate with tumor mass, but also reflect tumor differentiation, and are almost always high in patients with a palpable tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/5\">",
"     5",
"    </a>",
"    ]. Most MTCs also secrete carcinoembryonic antigen (CEA), which, like calcitonin, can be used as a tumor marker [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In addition, the expression of CEA on MTC cells has led to the use of anti-CEA antibodies for immunotherapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23288?source=see_link&amp;anchor=H12#H12\">",
"     \"Chemotherapy and immunotherapy for medullary thyroid cancer\", section on 'Immunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thyroid function tests are normal in patients with MTC.",
"   </p>",
"   <p>",
"    There are several ultrasound features of thyroid nodules (eg, hypoechoic, microcalcifications) that are associated with thyroid cancer risk. However, there are no ultrasound features that are pathognomonic for thyroid cancer. Furthermore, the majority of studies evaluating suspicious ultrasound characteristics of nodules focused on papillary thyroid cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\", section on 'Criteria for identifying cancer'",
"    </a>",
"    .) In a small retrospective study examining the ultrasound characteristic of nodules that were histologically proven to be medullary and papillary thyroid cancer, 50 percent of MTC were solid and hypoechoic and 16 percent showed microcalcifications compared with 69.2 and 69.2 percent, respectively, for papillary thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/10\">",
"     10",
"    </a>",
"    ]. The presence of at least one suspicious ultrasound feature was almost equal in patients with medullary thyroid cancer (58.3 percent) and controls with benign nodules (55.5 percent), whereas it was significantly more frequent in patients with papillary thyroid cancer (100 percent). In other series, hypoechogenicity was present in 50 to 89 percent and microcalcifications in 30 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], and there was no difference in echogenicity or the presence or type of calcifications between MTC and papillary thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Large areas of calcification (macrocalcification) were noted in 16 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/10,12,13\">",
"     10,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rarely, the diagnosis of MTC is suggested by the presence of dense calcifications seen on x-rays or imaging of the anterior neck.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Inherited MTC",
"    </span>",
"    &nbsp;&mdash;&nbsp;MEN2 is subclassified into three distinct syndromes, each of which is transmitted in an autosomal dominant fashion and is associated with MTC: MEN2A, MEN2B, and familial medullary thyroid cancer (FMTC). These syndromes result from different mutations in the RET proto-oncogene. Hereditary MTC is typically bilateral and multicentric. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MEN2A is associated with MTC, pheochromocytoma, and primary parathyroid hyperplasia. While the penetrance of MTC is nearly 100 percent, there is inter- and intra-family variability in the specific pattern of the other disease manifestations.",
"     </li>",
"     <li>",
"      MEN2B shares the inherited predisposition to MTC and pheochromocytoma present in MEN2A, but does not include hyperparathyroidism. MTC occurs in almost all patients. The tumor develops at an earlier age and may be more aggressive than in MEN2A. Patients typically have a marfanoid habitus (but do not have Marfan's syndrome), mucosal neuromas, and intestinal ganglioneuromatosis.",
"     </li>",
"     <li>",
"      FMTC is a variant of MEN2A, in which there is a strong predisposition to MTC but not the other clinical manifestations of MEN2A (or 2B).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the index case, the clinical presentation and manifestations of MEN2-associated MTC are similar to those of sporadic MTC. The most common presentation is that of a solitary thyroid nodule or cervical lymphadenopathy. Early diagnosis by screening of \"at-risk\" family members in MEN2 kindreds is important because MTC is a life-threatening disease that can be cured or prevented by early thyroidectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link\">",
"     \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link\">",
"     \"Approach to therapy in multiple endocrine neoplasia type 2\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1589349\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of sporadic MTC is usually made after fine needle aspiration biopsy in a patient who has a solitary thyroid nodule (or a dominant nodule within a multinodular goiter) (",
"    <a class=\"graphic graphic_picture graphicRef56242 \" href=\"UTD.htm?30/6/30831\">",
"     picture 1",
"    </a>",
"    ). The sensitivity of fine needle aspiration is 50 to 80 percent, although higher sensitivity can be obtained by the addition of immunohistochemical staining for calcitonin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. If the clinical suspicion for MTC is high (eg, patient with diarrhea, flushing, and a thyroid nodule), calcitonin can be measured in the washout of the fine needle aspiration biopsy needle [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/16\">",
"     16",
"    </a>",
"    ], although this may not be readily available in many commercial laboratories.",
"   </p>",
"   <p>",
"    The use of serum calcitonin screening to complement ultrasound and fine needle aspiration in the routine diagnosis of thyroid nodules is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/17\">",
"     17",
"    </a>",
"    ]. Measurement of serum calcitonin has not been a part of the routine evaluation of patients with thyroid nodules in the United States. The high frequency of falsely high serum calcitonin values, the inability to confirm the high calcitonin by pentagastrin stimulation in the United States, and the accuracy of fine needle aspiration biopsy would argue against a change in this recommendation. Further, occasional patients with locoregional metastases or locally invasive MTC will have normal unstimulated serum calcitonin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/1\">",
"     1",
"    </a>",
"    ]. This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H15#H15\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Serum calcitonin concentration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9087292\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis in a patient presenting with a neck mass is extensive and varies with the age of the patient at presentation. The majority of these masses represent benign thyroid nodules and cysts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .) Neck masses that are not of thyroidal origin may be congenital (ie, vascular anomaly), inflammatory (lymph node enlargement), or other neoplastic (primary or metastatic disease) disorders. The differential diagnosis of a neck mass is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11608?source=see_link\">",
"     \"Differential diagnosis of a neck mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Falsely elevated calcitonin results may be obtained in patients with hypercalcemia, hypergastrinemia, neuroendocrine tumors, renal insufficiency, papillary and follicular thyroid carcinomas, goiter, and chronic autoimmune thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Furthermore, prolonged treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    (greater than two to four months), beta-blockers, and glucocorticoids have been associated with hypercalcitoninemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients diagnosed with MTC on the basis of cytologic evaluation of a thyroid nodule, evaluation should include measurement of serum calcitonin, carcinoembryonic antigen (CEA), ultrasonography of the neck (if not already performed), genetic testing for germline RET mutations, and biochemical evaluation for coexisting tumors, especially pheochromocytoma. Our approach outlined below is largely consistent with National Comprehensive Cancer Network (NCCN) and American Thyroid Association Guidelines for Management of Medullary Thyroid Cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1216809\">",
"    <span class=\"h2\">",
"     Serum calcitonin and CEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum calcitonin and CEA concentrations should be measured in patients diagnosed with MTC on the basis of cytologic evaluation of a thyroid nodule. These tests can establish that the tumor is capable of hypersecreting the hormones and, if so, the values can be compared to postoperative values. Postoperatively, results may provide a prognostic factor or indicate biochemical cure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 226 patients with MTC (50 percent sporadic MTC, 33 percent MEN2A, 1 percent MEN2B, and 16 percent familial MTC), preoperative serum calcitonin concentrations were significantly correlated with tumor size in both the sporadic and familial cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/24\">",
"     24",
"    </a>",
"    ]. In addition, among 45 patients who had a preoperative serum calcitonin concentration of 50",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    or less, 44 had normal concentrations after surgery. In contrast, only 50 of 120 patients with preoperative serum calcitonin concentrations higher than 50",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    had normal concentrations after surgery. In a second study of 224 patients with MTC, 28 of 45 patients (62 percent) without nodal metastases had normal calcitonin postoperatively, while only 18 of 177 (10 percent) of node positive patients had normal postoperative calcitonin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assessment of calcitonin and CEA doubling times postoperatively provide sensitive markers for progression and aggressiveness of metastatic MTC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. As an example, postoperative calcitonin doubling time was a prognostic factor for survival in a study of 65 patients followed for 3 to 30 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/26\">",
"     26",
"    </a>",
"    ]. Ten year survival was 8 percent, 37 percent, and 100 percent for doubling times under six months, between six months and two years, and greater than two years, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medullary thyroid cancer can spread by local invasion or metastasis within the neck or distantly [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/3,5\">",
"     3,5",
"    </a>",
"    ]. When MTC is diagnosed by fine needle aspiration biopsy, ultrasonography of the neck is indicated to look for cervical lymph node involvement.",
"   </p>",
"   <p>",
"    For patients with local lymph node metastases on ultrasound or with preoperative serum basal calcitonin &gt;400",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (indicating high risk of local or distant metastatic disease), additional imaging is required to assess for metastatic disease. In this setting, we suggest cross-sectional imaging including chest CT, neck CT, three-phase contrast-enhanced liver CT or contrast-enhanced liver MRI.",
"   </p>",
"   <p>",
"    In patients suspected of having skeletal metastases, MRI may be superior to other imaging modalities [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend 18-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) imaging or somatostatin receptor imaging for routine initial screening for metastatic disease. The sensitivity of FDG-PET scanning for detecting metastatic disease is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], but improves with higher calcitonin levels (sensitivity 78 versus 20 percent for basal calcitonin value &gt; or &lt;1000",
"    <span class=\"nowrap\">",
"     pg/mL,",
"    </span>",
"    respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/31\">",
"     31",
"    </a>",
"    ]. The use of radionuclide imaging with 111-In-octreotide or 99m-Tc-DMSA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/32,33\">",
"     32,33",
"    </a>",
"    ] is not currently recommended for routine initial screening for metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/21\">",
"     21",
"    </a>",
"    ]. However, three patients have been described who had regional and distant metastases of MTC detected by somatostatin receptor scintigraphy but not by CT scan [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/34\">",
"     34",
"    </a>",
"    ]. How to select patients with a negative CT scan to undergo somatostatin receptor scintigraphy is not clear. Scanning may be more useful in localizing residual or recurrent disease after primary therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1589190\">",
"    <span class=\"h2\">",
"     Genetic screening in sporadic MTC",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important question is what proportion of patients with apparently sporadic MTC have unsuspected",
"    <strong>",
"     germline",
"    </strong>",
"    mutations in the RET proto-oncogene (the underlying defect in MEN2) and, therefore, have heritable disease. Germline RET mutations have been identified in small numbers of patients, although the frequency is variable across studies. Studies of unselected patients with MTC have found, on average, that about 6 to 7 percent (range 1.5 to 24 percent) have germline RET mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/35-39\">",
"     35-39",
"    </a>",
"    ]. In one report, 35 of 482 patients (7.3 percent) with apparently sporadic MTC had mutations, and in 18 of these 35, gene carriers were identified in relatives [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/39\">",
"     39",
"    </a>",
"    ]. Seventy-five percent of the familial medullary cases had no prior family history.",
"   </p>",
"   <p>",
"    Based upon these observations, we recommend germline RET testing in all patients with newly diagnosed C cell hyperplasia or apparently sporadic MTC. Initial germline testing in patients with C cell hyperplasia or apparently sporadic MTC should include sequencing of exons 10, 11, and 13 through 16 of the RET gene. Sequencing of the remaining exons in the RET gene should be considered in patients with clinical features or family history highly suggestive of hereditary medullary syndromes who demonstrate no mutations in exons 10, 11, or 13 through 16 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the index patient is positive for a germline mutation, family members should be screened. For the occasional kindred in which familial disease is present but a RET abnormality cannot be identified, family members at risk for MTC will need annual screening with measurement of calcium-stimulated serum calcitonin concentrations beginning at age five and continuing to at least age 35. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link&amp;anchor=H1589724#H1589724\">",
"     \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\", section on 'Screening of family members in MEN2 kindreds'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A much higher percentage (approximately 60 percent) of patients with sporadic MTC have",
"    <strong>",
"     somatic",
"    </strong>",
"    (acquired) mutations in the RET gene within the tumor cells (",
"    <a class=\"graphic graphic_table graphicRef85653 \" href=\"UTD.htm?23/5/23643\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. These mutations are present only in the tumor cells and are not detected by standard genetic testing, ie, using leukocyte DNA. Somatic RET mutations correlate with lymph node metastases, persistent disease, and lower survival [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/44\">",
"     44",
"    </a>",
"    ]. However, in one study, it was only mutations in exons 15 and 16 of the RET gene that were associated with the worse prognosis, while those in other exons had a more indolent course [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/43\">",
"     43",
"    </a>",
"    ]. Since it is unclear how knowledge of a specific somatic (acquired) RET mutation should impact clinical management, we do not routinely test tumor samples.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Testing for coexisting tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients require biochemical evaluation for coexisting tumors (particularly pheochromocytoma and hyperparathyroidism) prior to thyroidectomy. For patients with unknown RET mutational status and for patients who have a germline RET mutation, we measure serum calcium (to rule out hyperparathyroidism requiring concomitant surgical intervention) and plasma fractionated metanephrines (as the initial screen for pheochromocytoma). Normal plasma fractionated metanephrines values exclude a symptomatic catecholamine-secreting neoplasm, but mildly elevated values of normetanephrine could be falsely positive, in which case additional evaluations including 24-urinary fractionated metanephrines, catecholamines, and imaging may be required to effectively rule in or rule out pheochromocytoma prior to surgery. Adrenal imaging should not be performed unless there is biochemical evidence of a pheochromocytoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=see_link\">",
"     \"Clinical presentation and diagnosis of pheochromocytoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a patient with negative RET proto-oncogene testing and no family history of MEN2 syndrome, biochemical testing for coexisting tumors is typically not required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pTNM criteria for clinicopathologic tumor staging adopted by The Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC) are based upon tumor size and the presence or absence of extrathyroidal invasion, local and regional nodal metastases, and distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &mdash; MTCs that are less than 2 cm in diameter without evidence of disease outside of the thyroid gland",
"     </li>",
"     <li>",
"      Stage II &mdash; Any tumor between 2 and 4 cm without evidence of extrathyroidal disease",
"     </li>",
"     <li>",
"      Stage III &mdash; Any tumor greater than 4 cm, or level VI nodal metastases or microscopic extrathyroidal invasion regardless of tumor size",
"     </li>",
"     <li>",
"      Stage IV &mdash; Any distant metastases, or lymph node involvement outside of level VI, or gross soft tissue extension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study evaluated the prognostic significance of a previous TNM staging scheme in patients with MTC, most of whom were treated by total thyroidectomy and then followed for a median of four years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/2\">",
"     2",
"    </a>",
"    ]. Although the follow-up was short, mortality due to MTC was 0 percent in patients with stage I disease, 13 percent in stage II, 56 percent in stage III, and 100 percent in stage IV [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative staging classification proposed by DeGroot [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/46\">",
"     46",
"    </a>",
"    ] forms the basis for staging in a multicenter thyroid cancer registry [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/47\">",
"     47",
"    </a>",
"    ]. In this scheme, stage I disease is localized to the thyroid and stage II is limited to the thyroid or locoregional nodes. Extrathyroidal or extranodal extension characterizes stage III disease, and distant metastases are stage IV. Survival significantly declines with increasing stage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/1\">",
"     1",
"    </a>",
"    ]. The presence of either stage III or IV disease increases the likelihood of death due to MTC at least sevenfold, and the median disease-specific survival is only three to five years in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9560/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, lymph node metastases are already present in approximately 50 percent of patients at the time of initial surgery, unless the cancer was found by screening a family with a known RET mutation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38263?source=see_link&amp;anchor=H3#H3\">",
"     \"Medullary thyroid cancer: Treatment and prognosis\", section on 'Initial surgical therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medullary thyroid cancer (MTC) is a neuroendocrine tumor of the parafollicular or C cells of the thyroid gland; it accounts for approximately 3 to 5 percent of thyroid carcinomas. A characteristic feature of this tumor is the production of calcitonin. Most cases are sporadic (",
"      <a class=\"graphic graphic_table graphicRef85653 \" href=\"UTD.htm?23/5/23643\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common presentation of sporadic MTC (in 75 to 95 percent of patients) is a solitary thyroid nodule. In most patients, the disease has already metastasized at the time of diagnosis. Basal serum calcitonin concentrations usually correlate with tumor mass, but also reflect tumor differentiation, and are almost always high in patients with a palpable tumor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of sporadic MTC is usually made after fine needle aspiration biopsy in a patient who has a solitary thyroid nodule (or a dominant nodule within a multinodular goiter) (",
"      <a class=\"graphic graphic_picture graphicRef56242 \" href=\"UTD.htm?30/6/30831\">",
"       picture 1",
"      </a>",
"      ). The sensitivity of fine needle aspiration is improved by the addition of immunohistochemical staining for calcitonin. The use of serum calcitonin to complement FNA in the routine diagnosis of thyroid nodules is controversial. (See",
"      <a class=\"local\" href=\"#H1589349\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link&amp;anchor=H15#H15\">",
"       \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Serum calcitonin concentration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients diagnosed with MTC on the basis of cytologic evaluation of a thyroid nodule, evaluation should include measurement of serum calcitonin, carcinoembryonic antigen (CEA), ultrasonography of the neck (if not already performed), genetic testing for germline RET mutations, and biochemical evaluation for coexisting tumors, especially pheochromocytoma. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with apparently sporadic MTC have unsuspected germline RET mutations (the underlying defect in MEN2) and, therefore, heritable disease. We offer germline RET testing to all patients with newly diagnosed C cell hyperplasia or apparently sporadic MTC. (See",
"      <a class=\"local\" href=\"#H1589190\">",
"       'Genetic screening in sporadic MTC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Given the possibility that any patient with MTC may have MEN2, if results of germline RET testing are unknown (or positive), preoperative testing must also include measurement of serum calcium (to rule out hyperparathyroidism requiring concomitant surgical intervention) and testing for pheochromocytoma. We suggest plasma fractionated metanephrines as the initial screen for pheochromocytoma. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Testing for coexisting tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of MTC is discussed in detail separately. MEN2 is also reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38263?source=see_link\">",
"       \"Medullary thyroid cancer: Treatment and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=see_link\">",
"       \"Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=see_link\">",
"       \"Classification and genetics of multiple endocrine neoplasia type 2\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=see_link\">",
"       \"Approach to therapy in multiple endocrine neoplasia type 2\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/1\">",
"      Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984; 63:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/2\">",
"      Dottorini ME, Assi A, Sironi M, et al. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996; 77:1556.",
"     </a>",
"    </li>",
"    <li>",
"     Gagel RF, Hoff AO, Cote GJ. Medullary thyroid carcinoma. In: Werner &amp; Ingbar's The Thyroid, 9th, Braverman LE, Utiger RD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.967.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/4\">",
"      Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer 2000; 88:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/5\">",
"      Pacini F, Castagna MG, Cipri C, Schlumberger M. Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) 2010; 22:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/6\">",
"      Machens A, Hauptmann S, Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg 2007; 31:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/7\">",
"      Scheuba C, Kaserer K, Bieglmayer C, et al. Medullary thyroid microcarcinoma recommendations for treatment - a single-center experience. Surgery 2007; 142:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/8\">",
"      Machens A, Ukkat J, Hauptmann S, Dralle H. Abnormal carcinoembryonic antigen levels and medullary thyroid cancer progression: a multivariate analysis. Arch Surg 2007; 142:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/9\">",
"      Busnardo B, Girelli ME, Simioni N, et al. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984; 53:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/10\">",
"      Trimboli P, Nasrollah N, Amendola S, et al. Should we use ultrasound features associated with papillary thyroid cancer in diagnosing medullary thyroid cancer? Endocr J 2012; 59:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/11\">",
"      Choi N, Moon WJ, Lee JH, et al. Ultrasonographic findings of medullary thyroid cancer: differences according to tumor size and correlation with fine needle aspiration results. Acta Radiol 2011; 52:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/12\">",
"      Lee S, Shin JH, Han BK, Ko EY. Medullary thyroid carcinoma: comparison with papillary thyroid carcinoma and application of current sonographic criteria. AJR Am J Roentgenol 2010; 194:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/13\">",
"      Kim SH, Kim BS, Jung SL, et al. Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Korean J Radiol 2009; 10:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/14\">",
"      Bugalho MJ, Santos JR, Sobrinho L. Preoperative diagnosis of medullary thyroid carcinoma: fine needle aspiration cytology as compared with serum calcitonin measurement. J Surg Oncol 2005; 91:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/15\">",
"      Bhanot P, Yang J, Schnadig VJ, Logro&ntilde;o R. Role of FNA cytology and immunochemistry in the diagnosis and management of medullary thyroid carcinoma: report of six cases and review of the literature. Diagn Cytopathol 2007; 35:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/16\">",
"      Kudo T, Miyauchi A, Ito Y, et al. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid 2007; 17:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/17\">",
"      Costante G, Filetti S. Early diagnosis of medullary thyroid carcinoma: is systematic calcitonin screening appropriate in patients with nodular thyroid disease? Oncologist 2011; 16:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/18\">",
"      Toledo SP, Louren&ccedil;o DM Jr, Santos MA, et al. Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma. Clinics (Sao Paulo) 2009; 64:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/19\">",
"      Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med 2005; 142:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/20\">",
"      Erdogan MF, Gursoy A, Kulaksizoglu M. Long-term effects of elevated gastrin levels on calcitonin secretion. J Endocrinol Invest 2006; 29:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/21\">",
"      American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19:565.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on August 20, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/23\">",
"      Machens A, Hauptmann S, Dralle H. Medullary thyroid cancer responsiveness to pentagastrin stimulation: an early surrogate parameter of tumor dissemination? J Clin Endocrinol Metab 2008; 93:2234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/24\">",
"      Cohen R, Campos JM, Sala&uuml;n C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab 2000; 85:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/25\">",
"      Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005; 90:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/26\">",
"      Barbet J, Campion L, Kraeber-Bod&eacute;r&eacute; F, et al. Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2005; 90:6077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/27\">",
"      Laure Giraudet A, Al Ghulzan A, Aup&eacute;rin A, et al. Progression of medullary thyroid carcinoma: assessment with calcitonin and carcinoembryonic antigen doubling times. Eur J Endocrinol 2008; 158:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/28\">",
"      Miralli&eacute; E, Vuillez JP, Bardet S, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab 2005; 90:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/29\">",
"      Oudoux A, Salaun PY, Bournaud C, et al. Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy. J Clin Endocrinol Metab 2007; 92:4590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/30\">",
"      Giraudet AL, Vanel D, Leboulleux S, et al. Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels. J Clin Endocrinol Metab 2007; 92:4185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/31\">",
"      Ong SC, Sch&ouml;der H, Patel SG, et al. Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 2007; 48:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/32\">",
"      Bern&aacute; L, Cabezas R, Mora J, et al. 111In-octreotide and 99mTc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma. J Endocrinol 1995; 144:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/33\">",
"      Udelsman R, Ball D, Baylin SB, et al. Preoperative localization of occult medullary carcinoma of the thyroid gland with single-photon emission tomography dimercaptosuccinic acid. Surgery 1993; 114:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/34\">",
"      Krausz Y, Rosler A, Guttmann H, et al. Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid. Clin Nucl Med 1999; 24:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/35\">",
"      Eng C, Mulligan LM, Smith DP, et al. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995; 43:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/36\">",
"      Zedenius J, Wallin G, Hamberger B, et al. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s. Hum Mol Genet 1994; 3:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/37\">",
"      Wohllk N, Cote GJ, Bugalho MM, et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81:3740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/38\">",
"      Decker RA, Peacock ML, Borst MJ, et al. Progress in genetic screening of multiple endocrine neoplasia type 2A: is calcitonin testing obsolete? Surgery 1995; 118:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/39\">",
"      Elisei R, Romei C, Cosci B, et al. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 2007; 92:4725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/40\">",
"      Moline J, Eng C. Multiple endocrine neoplasia type 2: an overview. Genet Med 2011; 13:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/41\">",
"      Romei C, Elisei R, Pinchera A, et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996; 81:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/42\">",
"      Marsh DJ, Learoyd DL, Andrew SD, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1996; 44:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/43\">",
"      Moura MM, Cavaco BM, Pinto AE, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 2009; 100:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/44\">",
"      Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008; 93:682.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer (AJCC). Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al. (Eds), Springer-Verlag, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/46\">",
"      DeGroot LJ. Thyroid carcinoma. Med Clin North Am 1975; 59:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9560/abstract/47\">",
"      Sherman, SI, Brierley, J, Sperling, M, Maxon III, HR. Initial analysis of staging and outcomes from a prospective multicenter study of treatment of thyroid carcinoma. Thyroid 1996; 6 Suppl 1:S39.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7848 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9560=[""].join("\n");
var outline_f9_21_9560=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1589428\">",
"      Sporadic MTC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Inherited MTC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1589349\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9087292\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1216809\">",
"      Serum calcitonin and CEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1589190\">",
"      Genetic screening in sporadic MTC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Testing for coexisting tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7848\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7848|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/6/30831\" title=\"picture 1\">",
"      Medullary thyroid carcinoma FNA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7848|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/5/23643\" title=\"table 1\">",
"      Classification MTC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/42/8872?source=related_link\">",
"      Approach to therapy in multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23288?source=related_link\">",
"      Chemotherapy and immunotherapy for medullary thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/33/41495?source=related_link\">",
"      Classification and genetics of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/16/22794?source=related_link\">",
"      Clinical manifestations and diagnosis of multiple endocrine neoplasia type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/14/23786?source=related_link\">",
"      Clinical presentation and diagnosis of pheochromocytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11608?source=related_link\">",
"      Differential diagnosis of a neck mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/23/38263?source=related_link\">",
"      Medullary thyroid cancer: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_21_9561="Types of insomnia";
var content_f9_21_9561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Types of insomnia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/21/9561/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9561/contributors\">",
"     Michael H Bonnet, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9561/contributors\">",
"     Donna L Arand, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/21/9561/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9561/contributors\">",
"     Ruth Benca, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/21/9561/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9561/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/21/9561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a patient presents with insomnia, the clinician should look for a coexisting medical condition, psychiatric disorder, neurologic disease, sleep disorder, medication, or drug that is associated with insomnia. Insomnia is classified as \"insomnia associated with\" the coexisting condition if such a condition is identified. It is otherwise considered an independent disorder.",
"   </p>",
"   <p>",
"    The types of insomnia are described here. The definition, epidemiology, clinical features, consequences, diagnostic evaluation, and treatment of insomnia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=see_link\">",
"     \"Overview of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=see_link\">",
"     \"Clinical features and diagnosis of insomnia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link\">",
"     \"Treatment of insomnia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INSOMNIA WITH A SHORT DURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several types of insomnia typically have a short duration (ie, less than three months).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute insomnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute insomnia lasts for less than three months and is temporally related to an identifiable stressor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/1\">",
"     1",
"    </a>",
"    ]. Synonyms for acute insomnia include adjustment insomnia, short-term insomnia, stress-related insomnia, and transient insomnia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of insomnia\", section on 'Types of insomnia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute insomnia is expected to resolve when the stressor resolves or when the individual adapts to it. Stressors can be physical, psychological, psychosocial, interpersonal, or environmental:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Changes in the type or level of background noise",
"     </li>",
"     <li>",
"      Changes in the bedroom, such as a different bed or different furnishings, lighting, temperature, or occupants",
"     </li>",
"     <li>",
"      Consumption of or withdrawal from caffeine, nicotine, alcohol, or foods or beverages that contain these substances",
"     </li>",
"     <li>",
"      Stressful life events, such as loss of a loved one, divorce, loss of employment, arguments, particularly happy or sad events, work demands, or school demands",
"     </li>",
"     <li>",
"      Acute or chronic injuries or illnesses, particularly those causing pain or discomfort",
"     </li>",
"     <li>",
"      Medications or illicit drugs that have stimulant properties such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      , beta blockers, glucocorticoids, thyroxine, bronchodilators, or amphetamines (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17127?source=see_link\">",
"       \"The effects of medications on sleep quality and sleep architecture\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Withdrawal from central nervous system depressant medications",
"     </li>",
"     <li>",
"      Nursing home or hospital admission",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stress-induced insomnia appears to be related to increased activation of arousal systems rather than decreased drive for sleep, according to animal studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Circadian rhythm sleep disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;The circadian rhythm is a pattern of physiologic events that cycle approximately every 24 hours. The sleep-wake cycle is one example of a circadian rhythm.",
"   </p>",
"   <p>",
"    Circadian rhythm sleep disorders occur when the sleep-wake cycle is violated by trying to stay awake when physiologic conditions favor sleep, or trying to sleep when physiologic conditions favor staying awake. Some circadian rhythm sleep disorders, such as jet lag and shift work, typically cause short-term or acute insomnia. Those circadian rhythm disorders that cause chronic insomnia are discussed later (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Sleep disorders'",
"    </a>",
"    below)",
"   </p>",
"   <p>",
"    A change in habitual sleep time (ie, staying up later than usual) can also cause insomnia due to violation of an individual&rsquo;s normal sleep-wake cycle, but this is generally not classified as a circadian rhythm sleep disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=see_link&amp;anchor=H7#H7\">",
"     \"Classification of sleep disorders\", section on 'Circadian rhythm sleep disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Jet lag",
"    </span>",
"    &nbsp;&mdash;&nbsp;Jet lag is a circadian rhythm sleep disorder that is caused by travel across time zones. The traveler's sleep-wake cycle becomes out of sync with the time of day. Its severity is related to the number of time zones crossed, the direction of travel (traveling east is usually more difficult than traveling west), and the age of the traveler [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/1,3\">",
"     1,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals whose sleep-wake cycle is longer than 24 hours tolerate travel from east to west better than individuals whose circadian rhythm is 24 hours or shorter because the longer sleep-wake cycle is better synchronized with the longer day that results from the time change. Conversely, individuals whose sleep-wake cycle is shorter than 24 hours tolerate travel from west to east better than individuals whose sleep-wake cycle is 24 hours or longer.",
"   </p>",
"   <p>",
"    Suggestions for individuals who anticipate insomnia due to jet lag are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef54556 \" href=\"UTD.htm?31/37/32347\">",
"     table 1",
"    </a>",
"    ). Circadian rhythms normally adjust to such travel across time zones, but the maximum rate of adjustment seldom exceeds two to three hours per day. Thus, realignment to a new time zone may take several days. Adjustment may be accelerated by manipulation of controlling factors, such as bright light, activity and sleep, social contact, and the hormone melatonin. These interventions are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=see_link\">",
"     \"Jet lag\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Shift work",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia related to shift work is primarily found among individuals who work the night shift (ie, third shift). This includes approximately 20 percent of workers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/4\">",
"     4",
"    </a>",
"    ]. Affected night shift workers are sleepy at work and while driving home in the morning, but have difficulty maintaining sleep past noon. The sleep problems can be resolved by transferring from the night shift or by adopting a daily sleep routine that is consistent seven days per week. Chronic insomnia may develop in individuals who work the night shift on either a rotating or permanent basis. This is discussed below. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Circadian rhythm sleep disorders'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     High altitude insomnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with high altitude insomnia develop insomnia in conjunction with other features of high altitude disease, such as fatigue, headache, loss of appetite, and Cheyne-Stokes breathing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/5\">",
"     5",
"    </a>",
"    ]. This occurs upon ascent to altitudes higher than 4000 meters. The severity of the sleep disturbance is directly proportional to the height of ascent. Those who live at high altitudes become acclimatized and tend to sleep normally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Cheyne-Stokes breathing associated with high altitude insomnia occurs because peripheral chemoreceptors are stimulated by hypobaric hypoxemia, which causes hyperventilation. This results in hypocapnia and respiratory alkalosis, which suppresses ventilation and allows the carbon dioxide to rise. Hypercapnia stimulates hyperventilation and the cycle repeats. This abnormal breathing pattern causes repeated awakenings and sleep fragmentation that can be exacerbated by stress, uncomfortable sleeping environments, and cold temperatures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INSOMNIA WITH A LONGER DURATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many types of insomnia generally have a duration that is longer than one month. Such insomnia is found in about 10 percent of the population, with at least 80 percent continuing to report insomnia symptoms two or more years after onset [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Inadequate sleep hygiene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep hygiene refers to habits that maintain or promote good sleep. Patients with insomnia related to inadequate sleep hygiene have a pattern of daily life activities that is not conducive to quality sleep and daytime alertness. Inadequate sleep hygiene is the primary diagnosis given to 5 to 10 percent of patients with insomnia who are evaluated in sleep centers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/1\">",
"     1",
"    </a>",
"    ]. The following are examples of inappropriate sleep hygiene:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Irregular sleep schedule (eg, frequent daytime naps, irregular sleep or wake times, excessive time in bed)",
"     </li>",
"     <li>",
"      Routine use of sleep disturbing substances (eg, alcohol, caffeine, nicotine) before bedtime",
"     </li>",
"     <li>",
"      Mentally or physically stimulating activities before bedtime",
"     </li>",
"     <li>",
"      Frequent use of the bed or bedroom for activities that are not related to sleep (eg, studying, planning, snacking)",
"     </li>",
"     <li>",
"      Failure to maintain a comfortable sleep environment (eg, noisy, bright, too hot, or too cold)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Psychophysiological insomnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychophysiological insomnia is also called primary insomnia, chronic insomnia, learned insomnia, or conditioned insomnia. It is characterized by insomnia associated with physiologic activation that can be identified by cardiac, metabolic, hormonal, or electroencephalographic (EEG) measures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Psychophysiological insomnia is the underlying problem in approximately 15 percent of patients with insomnia who are evaluated at sleep centers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/1,13\">",
"     1,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Psychophysiological insomnia is typically associated with and facilitated by learned sleep-preventing behaviors. Patients with psychophysiological insomnia find it difficult to relax and have increasing mental content (ie, \"racing thoughts\") when they try to fall asleep. They frequently focus on their inability to fall asleep and start to worry, resulting in greater inability to fall asleep and more anxiety. Patients may focus on the perceived negative impact of lack of sleep on their ability to perform the next day. The poor sleep, intrusive thoughts, and worry can then become associated with the bedroom and sleep setting to produce a chronic pattern of poor sleep and associated consequences. As a result, some patients sleep better away from home because they are away from the factors that help to maintain their insomnia.",
"   </p>",
"   <p>",
"    Occasional or situational insomnia with heightened physiological arousal generally precedes the onset of psychophysiological insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/14\">",
"     14",
"    </a>",
"    ]. It is hypothesized that such a predisposition, combined with stressful life events and inappropriate coping, can lead to psychophysiological insomnia. First-degree relatives may suffer from similar sleep problems, suggesting a possible genetic component [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/15\">",
"     15",
"    </a>",
"    ]. Although affected individuals are overly concerned and focused on the sleep problem, they do not suffer from generalized anxiety, phobic, or other psychiatric disorders.",
"   </p>",
"   <p>",
"    Insomnia symptoms may be a consequence of central nervous system activation and not simply related to loss of sleep or poor quality sleep. This is supported by several observations. First, chronic poor sleep alone does not produce the spectrum of complaints reported by most patients, unless it is accompanied by physiological activation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Next, physiological activation is associated with insomnia symptoms even when sleep quality is relatively good according to EEG criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/18\">",
"     18",
"    </a>",
"    ]. Finally, patients do not report worse sleep quality or other insomnia symptoms if their sleep time is systematically reduced for a week in the absence of physiological stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Idiopathic insomnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic insomnia is also called childhood onset insomnia or life-long insomnia. Patients have lifelong difficulty initiating and maintaining sleep, resulting in poor daytime function. Idiopathic insomnia begins insidiously during infancy or early childhood and occurs in 1 percent or less of young adults and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of the syndrome is unknown. However, many patients have a history of learning disabilities or attention deficit hyperactivity disorder during childhood without identifiable neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/1\">",
"     1",
"    </a>",
"    ]. It is possible that a neurochemical imbalance exists, either in the arousal (hyperactivity) or sleep-promoting neurons (hypoactivity). Clustering in families may also exist [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. Idiopathic insomnia can only be diagnosed after concomitant medical, neurologic, and psychiatric problems have been excluded.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Behavioral insomnia of childhood",
"    </span>",
"    &nbsp;&mdash;&nbsp;Behavioral insomnia of childhood describes children who require specific (ie, learned) circumstances to fall asleep, such as the presence of a parent or favorite toy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/1\">",
"     1",
"    </a>",
"    ]. Absence of the required object results in either sleep onset insomnia or difficulty returning to sleep. Behavioral insomnia of childhood may exist to some extent in 10 to 30 percent of children beginning at six months of age. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36806?source=see_link&amp;anchor=H3#H3\">",
"     \"Behavioral sleep problems in children\", section on 'Behavioral insomnia of childhood'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Paradoxical insomnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paradoxical insomnia is also called sleep state misperception, subjective insomnia, pseudoinsomnia, and sleep hypochondriasis. Patients with paradoxical insomnia consistently complain of insomnia, even on nights when polysomnography reveals apparently normal EEG sleep stages. Such patients are believed to consistently overestimate how long it takes to fall asleep and to underestimate their total sleep time. The incidence of paradoxical insomnia is unknown because polysomnography is required to identify these patients.",
"   </p>",
"   <p>",
"    Patients with paradoxical insomnia have high frequency EEG activity and an increased whole body metabolic rate during sleep, suggesting that increased central nervous system arousal during sleep may be responsible for the subjective estimates and daytime dysphoria [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. Paradoxical insomnia cannot be easily differentiated from psychophysiological insomnia without comparative polysomnography because many patients with insomnia underestimate their sleep time, especially when there is central nervous system activation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Insomnia associated with another condition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia associated with a medical condition exists when the insomnia is temporally related to a medical condition that is known to disrupt sleep. Similarly, insomnia associated with a psychiatric disorder and insomnia associated with substance use are temporally related to the onset of a psychiatric disorder or use of a substance that is known to disrupt sleep. In each of these three insomnia conditions, the sleep disturbance both coexists and is directly related to the condition or substance. Insomnia may also be associated with a neurologic disease, sleep disorder, medication, or drug (",
"    <a class=\"graphic graphic_table graphicRef50646 \" href=\"UTD.htm?39/17/40221\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Insomnia associated with a psychiatric disorder is the most common diagnosis for patients with insomnia who are seen in a sleep center, occurring in about 3 percent of the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/13\">",
"     13",
"    </a>",
"    ]. Insomnia associated with substance abuse is estimated to occur in about 0.2 percent of the general population, while insomnia associated with a medical condition is estimated to occur in about 0.5 percent of the general population. The latter occurs in a much higher proportion in certain clinical populations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Medical conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia that follows a chronic course can be a direct result of a medical illness or related to the medications required to treat the medical illness. Approximately 10 percent of patients with insomnia lasting greater than one month have a coexisting medical condition or take medication [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/13\">",
"     13",
"    </a>",
"    ]. Conversely, approximately 40 percent of patients with a medical problem have insomnia that follows a chronic course, compared to 8 percent in a control population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/21\">",
"     21",
"    </a>",
"    ]. Medical conditions that are often associated with chronic insomnia include pulmonary disease, pain, and heart failure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary Disease &ndash; More than 50 percent of patients with pulmonary disease report insomnia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. The high prevalence of insomnia in this patient population may be related to events that occur when the patient lies down and tries to fall asleep: work of breathing increases, secretions pool in the airways,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nocturnal bronchoconstriction may occur [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/23\">",
"       23",
"      </a>",
"      ]. Insomnia may also be related to respiratory stimulant medication taken during the night.",
"     </li>",
"     <li>",
"      Pain &ndash; Approximately 30 to 50 percent of patients with cancer and 25 percent of patients with arthritis report insomnia due to pain [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/21,24\">",
"       21,24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Heart Failure &ndash; Approximately 30 percent of patients with heart failure may have insomnia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/8\">",
"       8",
"      </a>",
"      ]. The insomnia may be related to Cheyne-Stokes breathing or frequent awakenings due to nocturia caused by use of a diuretic. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"       \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Insomnia is also associated with rheumatologic disease (eg, arthritis, fibromyalgia), ischemic heart disease, urologic disease (eg, benign prostatic hyperplasia), endocrine disease (eg, menopause, diabetes mellitus, hyperthyroidism), and gastrointestinal disease (eg, gastroesophageal reflux). Findings that suggest that these disorders may be playing a role are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of insomnia\", section on 'Medical history'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic insomnia and psychiatric disorders frequently coexist (",
"    <a class=\"graphic graphic_table graphicRef50646 \" href=\"UTD.htm?39/17/40221\">",
"     table 2",
"    </a>",
"    ). In one study, nearly 45 percent of patients with chronic insomnia also had a psychiatric condition, such as depression or anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/13\">",
"     13",
"    </a>",
"    ]. Findings that suggest a potential psychiatric disorder are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of insomnia\", section on 'Medical history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients typically attribute their anxiety or depression to difficulty sleeping and present to their primary care clinician for treatment of the insomnia. Clinicians have historically assumed that the insomnia is secondary to the psychiatric disorder and have treated the psychiatric condition with the expectation that the insomnia will improve as the psychiatric condition improves. However, the insomnia frequently does not improve, suggesting that the insomnia is a comorbidity and not a consequence of the psychiatric disorder in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insomnia frequently precedes and may predict the development of a number of psychiatric illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. In one study, individuals with insomnia were 34 times more likely to develop a new psychiatric disorder (particularly major depression) within one year, compared to individuals without insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/28\">",
"     28",
"    </a>",
"    ]. Insomnia remained predictive for depression for many years.",
"   </p>",
"   <p>",
"    Depression:",
"   </p>",
"   <p>",
"    The diagnosis of depression requires patients to have a depressed mood plus at least four out of eight other symptoms. Insomnia is one of the eight symptoms. Two of the remaining seven symptoms are also diagnostic criteria for insomnia &mdash; daytime fatigue and difficulty thinking or concentrating during the day. This overlap of symptoms makes it likely that insomnia and depression will frequently coexist. In one study, insomnia was a symptom in approximately 80 percent of patients with depression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients frequently report the onset of insomnia prior to the development of depression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early morning awakening is a hallmark symptom of depression, but adolescents and young adults with depression may report difficulty initiating sleep instead. Depressed patients may also complain that they have not slept at all for one or more nights, although sleep recordings of these nights show reduced (not absent) sleep. Depressed patients have a reduced latency to REM sleep with increased REM in the first one-third of the night. Resolution of insomnia predicts a favorable response to the treatment of depression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=see_link\">",
"     \"Stages and architecture of normal sleep\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insomnia may not improve even if underlying depression is identified and treated. As a result, directed treatment of insomnia may be required. The evidence indicates that concurrent treatment of both depression and insomnia with a separate medication for each problem results in an increased likelihood of an effective treatment response for insomnia and more rapid control of depression at lower doses of the antidepressant medication [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anxiety:",
"   </p>",
"   <p>",
"    The diagnosis of generalized anxiety disorder requires patients to have anxiety plus at least three out of six other symptoms. Insomnia is one of the six symptoms. The remaining five symptoms are also diagnostic criteria for insomnia &mdash; fatigue, restlessness, difficulty concentrating, irritability, and muscle tension. This overlap of symptoms makes it likely that insomnia and anxiety will frequently coexist. In one study, insomnia was a symptom in approximately 80 percent of patients with anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insomnia can develop before, at the same time, or after the onset of anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/26\">",
"     26",
"    </a>",
"    ]. Among patients with insomnia alone, insomnia predicts the development of generalized anxiety disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/27\">",
"     27",
"    </a>",
"    ]. Insomnia is also commonly seen in patients who have panic disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=see_link\">",
"     \"Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=see_link\">",
"     \"Pharmacotherapy for panic disorder\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Substance abuse:",
"   </p>",
"   <p>",
"    Insomnia is a predictor of substance abuse, including alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/27\">",
"     27",
"    </a>",
"    ]. It predates alcohol dependence in the majority of alcoholics and predicts relapse to alcoholism among those who have achieved abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. Few studies have looked at the impact of insomnia treatment on alcoholism due to concerns about dependence on sleeping pills; however, one trial that randomly assigned 17 individuals recovering from alcohol dependence to receive either cognitive behavioral therapy or a placebo therapy found an equal number of relapse in both groups [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Posttraumatic stress disorder:",
"   </p>",
"   <p>",
"    Patients with posttraumatic stress disorder (PTSD) frequently have insomnia. Specifically, one review estimated that 70 to 90 percent of patients with PTSD have difficulty falling or staying asleep [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/35\">",
"     35",
"    </a>",
"    ]. This is frequently associated with nightmares and fear of falling asleep or returning to sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=see_link\">",
"     \"Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Neurologic diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly 70 percent of patients with neurologic disease report insomnia (",
"    <a class=\"graphic graphic_table graphicRef50646 \" href=\"UTD.htm?39/17/40221\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients with Parkinson disease, approximately 30 percent have insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/24\">",
"     24",
"    </a>",
"    ]. As Parkinson disease worsens, sleep deteriorates and a coexisting REM sleep behavior disorder may develop [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"     \"Clinical manifestations of Parkinson disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with Alzheimer disease, approximately 25 percent have insomnia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/38\">",
"     38",
"    </a>",
"    ]. The insomnia may be related to nocturnal agitation, delirium, and wandering, all of which may be caused by increased stage 1 sleep and awakenings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of behavioral symptoms related to dementia\", section on 'Sleep disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insomnia can be caused by a wide variety of medications (",
"    <a class=\"graphic graphic_table graphicRef50646 \" href=\"UTD.htm?39/17/40221\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/39\">",
"     39",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central nervous system stimulants, such as caffeine",
"     </li>",
"     <li>",
"      Respiratory stimulants, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"     </li>",
"     <li>",
"      Appetite suppressants",
"     </li>",
"     <li>",
"      Calcium channel blockers",
"     </li>",
"     <li>",
"      Antidepressants",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Tricyclic antidepressants are normally sedating, but some (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/5/10327?source=see_link\">",
"       protriptyline",
"      </a>",
"      ) can produce insomnia",
"     </li>",
"     <li>",
"      Monoamine oxidase inhibitor antidepressants are associated with insomnia in nearly 70 percent of patients",
"     </li>",
"     <li>",
"      Selective serotonin reuptake inhibitor antidepressants, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"       fluoxetine",
"      </a>",
"      , are associated with insomnia in 5 to 35 percent of patients",
"     </li>",
"     <li>",
"      Norepinephrine and dopamine reuptake inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"       bupropion",
"      </a>",
"      , are associated with insomnia in 5 to 20 percent of patients",
"     </li>",
"     <li>",
"      Selective serotonin and norepinephrine reuptake inhibitors, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/45/22233?source=see_link\">",
"       venlafaxine",
"      </a>",
"      , are associated with insomnia in 4 to 18 percent of patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta antagonists, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/15/10487?source=see_link\">",
"       pindolol",
"      </a>",
"      produce sleep onset insomnia, increased awakenings,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dreams",
"     </li>",
"     <li>",
"      Glucocorticoids, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and cortisol, are associated with increased wakefulness during the night. Insomnia may occur in 50 to 70 percent of patients who receive prednisone",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Sleep disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;In approximately 5 percent of patients with chronic insomnia, degraded sleep caused by another sleep disorder is the likely cause of the insomnia (",
"    <a class=\"graphic graphic_table graphicRef50646 \" href=\"UTD.htm?39/17/40221\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/13\">",
"     13",
"    </a>",
"    ]. Any patient suspected of having an underlying sleep disorder should be referred to a sleep center for further evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Some of the sleep disorders associated with insomnia are described in this section.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Restless legs syndrome &ndash; Restless legs syndrome (RLS) is characterized by an urge to move the legs. It is commonly accompanied by painful, creeping, itching, or jittery sensations in the legs. The urge to move the legs and the associated discomfort are relieved by moving the legs, but the relief only lasts for as long as movement continues. The symptoms of RLS are most common when patients lie down to attempt to fall asleep [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/42-45\">",
"       42-45",
"      </a>",
"      ]. As a result, an estimated 85 percent of patients with RLS have difficulty falling asleep [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/46\">",
"       46",
"      </a>",
"      ]. Patients are also likely to wake frequently during the night with discomfort in their legs. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"       \"Restless legs syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Periodic limb movement disorder &ndash; Periodic limb movement disorder (PLMD) is characterized by rhythmic limb movements during sleep. Patients most commonly dorsiflex the ankles or flex the knees and hips for 1 to 5 seconds with a consistent periodicity of 20 to 40 seconds [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/46\">",
"       46",
"      </a>",
"      ]. Occasionally, PLMD involves the upper limbs. The periodic limb movements may be accompanied by partial arousals, causing sleep fragmentation and difficulty maintaining sleep. Periodic limb movements are often seen in patients with RLS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link&amp;anchor=H16#H16\">",
"       \"Restless legs syndrome\", section on 'Periodic limb movements of sleep'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sleep apnea &ndash; Patients with sleep apnea have pauses in respiration during sleep that are frequently associated with brief arousals when they resume respiration. As a result, they often report frequent awakenings, poor sleep, or daytime deficits. Approximately 50 to 55 percent of patients being evaluated for sleep apnea report insomnia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/24,47\">",
"       24,47",
"      </a>",
"      ]. Conversely, nearly 30 percent of patients with insomnia have sleep apnea [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/48\">",
"       48",
"      </a>",
"      ]. In some cases, the insomnia does not improve despite successful treatment of the sleep apnea, indicating that the insomnia may be a comorbidity and not a consequence of the sleep apnea. In these cases, additional therapy for insomnia may be indicated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link\">",
"       \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=see_link\">",
"       \"Central sleep apnea: Risk factors, clinical presentation, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Circadian rhythm sleep disorders &ndash; The most common circadian rhythm sleep disorders cause insomnia with an acute course. However, circadian rhythm sleep disorders can also cause chronic insomnia. This includes patients who have minimal social or environmental time cues (eg, blind or bedridden patients), who work the night shift (shift work sleep disorder), or whose sleep-wake rhythm favors sleep later (delayed sleep phase syndrome) or earlier (advanced sleep phase syndrome) than the desired clock time. Each is described below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with few social or environmental time cues can develop a non-24 hour sleep rhythm based upon their internal circadian rhythm. As an example, patients whose sleep-wake rhythm is 26 hours will function normally if they sleep two hours later than they did the previous day. In contrast, they will be sleepy if awakened at the same time as on the previous day. Sleep and alertness will remain normal as long as these individuals go to sleep progressively later each night and arise progressively later each day (ie, free running). However, this is not practical if there are work or social requirements. Patients with circadian rhythm disorders can usually be controlled by having consistent arising times and using bright light or social factors in the morning to push the rhythm earlier or in the evening to push the rhythm later.",
"   </p>",
"   <p>",
"    Insomnia associated with shift work frequently follows an acute course. However, individuals who work rotating or permanent night shifts (usually five nights per week) often revert to a nocturnal sleep pattern on their off days to maintain contact with their family. As a result, their circadian rhythm never adjusts to the pattern of working at night, and they progress to chronic insomnia due to periodic circadian rhythm violation. This is referred to as shift work sleep disorder. It may resolve by transferring off the night shift or by adopting a consistent daily sleep routine seven days per week. Shift work sleep disorder has been associated with numerous medical and psychiatric problems, including gastrointestinal and cardiovascular symptoms, depression, and substance abuse [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Delayed sleep phase syndrome occurs in individuals, particularly young adults, who have difficulty falling asleep (ie, sleep onset insomnia) at desired times because their circadian rhythm is shifted later (ie, delayed). The misalignment is stable and normal sleep occurs once the individual falls asleep. However, it may be extremely difficult for these individuals to arise at normal times for school or work demands.",
"   </p>",
"   <p>",
"    Delayed sleep phase disorder can develop when individuals stay up late on weekend nights before going to bed early on Sunday night. This results in sleep onset insomnia and difficulty arising the next morning. Circadian rhythm disorders are best controlled by going to sleep and waking around the same time on all nights (ie, sleep hygiene).",
"   </p>",
"   <p>",
"    The delayed sleep phase syndrome exists in 5 to 10 percent of patients with insomnia in some sleep centers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/1\">",
"     1",
"    </a>",
"    ]. The mean age of onset of the sleep delayed phase syndrome is 20 years, but the problem often begins in adolescence. A family history of delayed phase syndrome exists in about 40 percent of patients. In addition, genetic factors such as polymorphism in the circadian clock gene are associated with delayed sleep phase syndrome.",
"   </p>",
"   <p>",
"    In contrast, advanced sleep phase syndrome occurs in individuals, particularly middle age and elderly adults, who have a sleep-wake rhythm that favors sleep earlier than the desired clock time. This causes early morning awakening. Sleep can be normal in such individuals if they accept an early bed time (eg, between 6 and 9 PM) and early wake time (eg, between 2 and 5 AM). Many such individuals try to stay up later at night, hoping that this will allow them to sleep later. However, they still awaken in the early morning and are often unable to return to sleep.",
"   </p>",
"   <p>",
"    Advanced sleep phase syndrome is estimated to have a prevalence of approximately 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9561/abstract/1\">",
"     1",
"    </a>",
"    ]. Its diagnosis is based on sleep logs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    characteristic actigraphic recordings over several days. An actigraph is a small device that is typically worn on the wrist of the nondominant hand where it measures gross motor activity.",
"   </p>",
"   <p>",
"    Early morning awakening due to advanced sleep phase syndrome should be distinguished from that due to depression. Patients with advanced sleep phase syndrome who go to sleep at an early time generally have a normal mood and normal sleep (including a normal latency to rapid eye movement [REM] sleep), as measured by polysomnography. In contrast, patients with depression typically have a shortened latency to REM sleep.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Unspecified insomnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unspecified insomnia refers to insomnia that does not fit into any of the above categories.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19602?source=see_link\">",
"       \"Patient information: Jet lag (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=see_link\">",
"       \"Patient information: Insomnia (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=see_link\">",
"       \"Patient information: Insomnia treatments (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When a patient presents with insomnia, the clinician should look for a coexisting medical condition, psychiatric disorder, neurologic disease, sleep disorder, medication, or drug that is associated with insomnia. Insomnia is classified as \"insomnia associated with\" the coexisting condition if such a condition is identified. It is otherwise considered an independent disorder. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Types of insomnia that typically last less than three months include acute insomnia, some circadian rhythm sleep disorders (eg, jet lag, shift work), and high altitude insomnia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Insomnia with a short duration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Types of insomnia that generally last longer than one month include inadequate sleep hygiene, psychophysiological insomnia, idiopathic insomnia, behavioral insomnia of childhood, paradoxical insomnia, and insomnia associated with a variety of medical conditions, psychiatric disorders, neurologic diseases, sleep disorders, medications, or drugs. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Insomnia with a longer duration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     International classification of sleep disorders: Diagnostic and coding manual, 2nd ed, American Academy of Sleep Medicine, Westchester, IL 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/2\">",
"      Cano G, Mochizuki T, Saper CB. Neural circuitry of stress-induced insomnia in rats. J Neurosci 2008; 28:10167.",
"     </a>",
"    </li>",
"    <li>",
"     Arendt J, Stone B, Skene DJ. Sleep disruption in jet lag and other circadian rhythm-related disorders. In: Principles and practice of sleep medicine, 4th ed, Kryger M, Roth T, Dement WC (Eds), Saunders, New York 2005.",
"    </li>",
"    <li>",
"     U.S. Congress, Office of Technology Assessment. Biological Rhythms: Implications for the Worker (OTA-BA-463). U.S. Government Printing Office; U.S. Congress, Office of Technology Assessment, Washington, DC, 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/5\">",
"      Nicholson AN, Smith PA, Stone BM, et al. Altitude insomnia: studies during an expedition to the Himalayas. Sleep 1988; 11:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/6\">",
"      Salvaggio A, Insalaco G, Marrone O, et al. Effects of high-altitude periodic breathing on sleep and arterial oxyhaemoglobin saturation. Eur Respir J 1998; 12:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/7\">",
"      Johnson EO, Roth T, Schultz L, Breslau N. Epidemiology of DSM-IV insomnia in adolescence: lifetime prevalence, chronicity, and an emergent gender difference. Pediatrics 2006; 117:e247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/8\">",
"      Katz DA, McHorney CA. Clinical correlates of insomnia in patients with chronic illness. Arch Intern Med 1998; 158:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/9\">",
"      Bonnet MH, Arand DL. Heart rate variability in insomniacs and matched normal sleepers. Psychosom Med 1998; 60:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/10\">",
"      Nofzinger EA, Buysse DJ, Germain A, et al. Functional neuroimaging evidence for hyperarousal in insomnia. Am J Psychiatry 2004; 161:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/11\">",
"      Vgontzas AN, Bixler EO, Lin HM, et al. Chronic insomnia is associated with nyctohemeral activation of the hypothalamic-pituitary-adrenal axis: clinical implications. J Clin Endocrinol Metab 2001; 86:3787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/12\">",
"      Perlis ML, Smith MT, Andrews PJ, et al. Beta/Gamma EEG activity in patients with primary and secondary insomnia and good sleeper controls. Sleep 2001; 24:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/13\">",
"      Ohayon MM. Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 2002; 6:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/14\">",
"      Bonnet MH, Arand DL. Situational insomnia: consistency, predictors, and outcomes. Sleep 2003; 26:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/15\">",
"      Bastien CH, Morin CM. Familial incidence of insomnia. J Sleep Res 2000; 9:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/16\">",
"      Bonnet MH, Arand DL. The consequences of a week of insomnia. Sleep 1996; 19:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/17\">",
"      Bonnet MH, Arand DL. Caffeine use as a model of acute and chronic insomnia. Sleep 1992; 15:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/18\">",
"      Bonnet MH, Arand DL. Physiological activation in patients with Sleep State Misperception. Psychosom Med 1997; 59:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/19\">",
"      Bonnet MH, Arand DL. The consequences of a week of insomnia. II: Patients with insomnia. Sleep 1998; 21:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/20\">",
"      Krystal AD, Edinger JD, Wohlgemuth WK, Marsh GR. NREM sleep EEG frequency spectral correlates of sleep complaints in primary insomnia subtypes. Sleep 2002; 25:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/21\">",
"      Taylor DJ, Mallory LJ, Lichstein KL, et al. Comorbidity of chronic insomnia with medical problems. Sleep 2007; 30:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/22\">",
"      George CF, Bayliff CD. Management of insomnia in patients with chronic obstructive pulmonary disease. Drugs 2003; 63:379.",
"     </a>",
"    </li>",
"    <li>",
"     Douglas N. Asthma and chronic obstructive pulmonary disease. In: Principles and practice of sleep medicine, 4th ed, Kryger M, Roth T, Dement WC (Eds), Saunders, New York 2005. p.1122.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/24\">",
"      Banno, K, Kryger, MH. Comorbid insomnia. Sleep Med Clin 2006; 1:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/25\">",
"      National Institutes of Health. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep 2005; 28:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/26\">",
"      Ohayon MM, Roth T. Place of chronic insomnia in the course of depressive and anxiety disorders. J Psychiatr Res 2003; 37:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/27\">",
"      Breslau N, Roth T, Rosenthal L, Andreski P. Sleep disturbance and psychiatric disorders: a longitudinal epidemiological study of young adults. Biol Psychiatry 1996; 39:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/28\">",
"      Ford DE, Kamerow DB. Epidemiologic study of sleep disturbances and psychiatric disorders. An opportunity for prevention? JAMA 1989; 262:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/29\">",
"      Krystal, AD. Psychiatric comorbidity: the case for treating insomnia. Sleep Med Clin 2006; 1:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/30\">",
"      Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006; 59:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/31\">",
"      Currie SR, Clark S, Rimac S, Malhotra S. Comprehensive assessment of insomnia in recovering alcoholics using daily sleep diaries and ambulatory monitoring. Alcohol Clin Exp Res 2003; 27:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/32\">",
"      Brower KJ, Aldrich MS, Robinson EA, et al. Insomnia, self-medication, and relapse to alcoholism. Am J Psychiatry 2001; 158:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/33\">",
"      Drummond SP, Gillin JC, Smith TL, DeModena A. The sleep of abstinent pure primary alcoholic patients: natural course and relationship to relapse. Alcohol Clin Exp Res 1998; 22:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/34\">",
"      Arnedt JT, Conroy DA, Armitage R, Brower KJ. Cognitive-behavioral therapy for insomnia in alcohol dependent patients: a randomized controlled pilot trial. Behav Res Ther 2011; 49:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/35\">",
"      Maher MJ, Rego SA, Asnis GM. Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management. CNS Drugs 2006; 20:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/36\">",
"      Lamarche LJ, De Koninck J. Sleep disturbance in adults with posttraumatic stress disorder: a review. J Clin Psychiatry 2007; 68:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/37\">",
"      Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006; 66:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/38\">",
"      Moran M, Lynch CA, Walsh C, et al. Sleep disturbance in mild to moderate Alzheimer's disease. Sleep Med 2005; 6:347.",
"     </a>",
"    </li>",
"    <li>",
"     Schweitzer PK. Drugs that disturb sleep and wakefulness. In: Principles and practice of sleep medicine, 4th ed, Kryger M, Roth T, Dement WC (Eds), Saunders, New York 2005. p.499.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/40\">",
"      Arand, DL, Burton, G, Bonnet, MH. When to order a sleep study and how to read the report - Part I. Primary Care Reports 2002; 8:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/41\">",
"      Arand, DL, Burton, G, Bonnet, MH. When to order a sleep study and how to read the report - Part II. Primary Care Reports 2002; 8:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/42\">",
"      Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003; 4:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/43\">",
"      Michaud M, Dumont M, Selmaoui B, et al. Circadian rhythm of restless legs syndrome: relationship with biological markers. Ann Neurol 2004; 55:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/44\">",
"      Phillips B, Young T, Finn L, et al. Epidemiology of restless legs symptoms in adults. Arch Intern Med 2000; 160:2137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/45\">",
"      Nichols DA, Allen RP, Grauke JH, et al. Restless legs syndrome symptoms in primary care: a prevalence study. Arch Intern Med 2003; 163:2323.",
"     </a>",
"    </li>",
"    <li>",
"     Montplaisir J, Allen RP, Walters AS, Ferini-Strambi L. Restless legs syndrome and periodic limb movements during sleep. In: Principles and practice of sleep medicine, 4th ed, Kryger M, Roth T, Dement WC (Eds), Saunders, New York 2005. p.839.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/47\">",
"      Krell SB, Kapur VK. Insomnia complaints in patients evaluated for obstructive sleep apnea. Sleep Breath 2005; 9:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/48\">",
"      Gooneratne NS, Gehrman PR, Nkwuo JE, et al. Consequences of comorbid insomnia symptoms and sleep-related breathing disorder in elderly subjects. Arch Intern Med 2006; 166:1732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9561/abstract/49\">",
"      Costa G. Shift work and occupational medicine: an overview. Occup Med (Lond) 2003; 53:83.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7690 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9561=[""].join("\n");
var outline_f9_21_9561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INSOMNIA WITH A SHORT DURATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute insomnia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Circadian rhythm sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Jet lag",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Shift work",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      High altitude insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INSOMNIA WITH A LONGER DURATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Inadequate sleep hygiene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Psychophysiological insomnia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Idiopathic insomnia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Behavioral insomnia of childhood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Paradoxical insomnia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Insomnia associated with another condition",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Medical conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Neurologic diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Unspecified insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7690\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7690|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/37/32347\" title=\"table 1\">",
"      Suggestions time zone shift",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/17/40221\" title=\"table 2\">",
"      Causes of chronic insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/60/36806?source=related_link\">",
"      Behavioral sleep problems in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=related_link\">",
"      Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11301?source=related_link\">",
"      Classification of sleep disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/36/41541?source=related_link\">",
"      Clinical features and diagnosis of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/0/32776?source=related_link\">",
"      Generalized anxiety disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=related_link\">",
"      High altitude illness: Physiology, risk factors, and general prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35861?source=related_link\">",
"      Jet lag",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/41/4758?source=related_link\">",
"      Overview of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/16/2306?source=related_link\">",
"      Patient information: Insomnia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/24/28035?source=related_link\">",
"      Patient information: Insomnia treatments (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19602?source=related_link\">",
"      Patient information: Jet lag (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/8/7305?source=related_link\">",
"      Pharmacotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27352?source=related_link\">",
"      Posttraumatic stress disorder: Epidemiology, pathophysiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=related_link\">",
"      Stages and architecture of normal sleep",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/46/17127?source=related_link\">",
"      The effects of medications on sleep quality and sleep architecture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_21_9562="Drugs that affect bone metabolism";
var content_f9_21_9562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drugs that affect bone metabolism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/21/9562/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9562/contributors\">",
"     Harold N Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/21/9562/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9562/contributors\">",
"     Marc K Drezner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/21/9562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/21/9562/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/21/9562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many drugs can affect bone metabolism. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    , cancer drugs and thyroid hormone can cause bone loss, while thiazide diuretics can minimize bone loss [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This topic will review the skeletal effects of some of these drugs. The effects of glucocorticoids, aromatase inhibitors, and thyroid hormone are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37545?source=see_link\">",
"     \"Evaluation and management of aromatase inhibitor-induced bone loss\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=see_link\">",
"     \"Bone disease with hyperthyroidism and thyroid hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DRUGS THAT MAY HAVE ADVERSE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anticoagulants",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    causes bone loss by decreasing bone formation. The few studies of the mechanism of bone loss have revealed decreased bone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/1,3\">",
"     1,3",
"    </a>",
"    ], increasing bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/1\">",
"     1",
"    </a>",
"    ], or both [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is usually given for brief periods of time, its adverse effect on the skeleton should be trivial. However, it may be given for a prolonged period during pregnancy, since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is relatively contraindicated in the first trimester due to its teratogenic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, most of the information concerning the adverse effects of heparin on bone comes from studies of pregnant women requiring anticoagulation.",
"   </p>",
"   <p>",
"    Chronic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy reduces bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In one study, for example, in 14 heparin-treated pregnant women and 14 untreated pregnant women, mean hip density fell significantly by about 5 percent in the women receiving heparin; there was no change in the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/6\">",
"     6",
"    </a>",
"    ]. Hip density decreased by more than 10 percent in 5 of the 14 women taking heparin (36 percent) versus none of the control group. Similar results were reported in another controlled study, which examined the effect of heparin on forearm density [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are many case reports and series of pregnant women with osteoporotic fractures during and after prolonged",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. One of the largest studies followed 184 pregnant women who were given heparin: four (2.2 percent) had osteoporotic vertebral fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/9\">",
"     9",
"    </a>",
"    ]. Although the incidence of fractures was low, they occurred in young women in whom osteoporotic fractures are extremely rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bone density increases postpartum after the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. It is unclear, however, if recovery is complete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low molecular weight (LMW) heparins may have less of an adverse effect on bone than unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, these trials were small and a larger, prospective observational study found no difference between the two heparin preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    decreases the tendency of blood to clot by inhibiting the vitamin K-dependent gamma-carboxylation of clotting factors II, VII, IX, and X [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/5\">",
"     5",
"    </a>",
"    ]. Non-carboxylated clotting factors do not bind to calcium and, therefore, cannot participate in the coagulation cascade. Similarly, warfarin inhibits the gamma-carboxylation of osteocalcin (a major protein of bone); non-carboxylated osteocalcin cannot to bind calcium effectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=see_link\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of the latter observation, it has been suspected that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    may adversely affect skeletal health. This hypothesis is indirectly supported by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean serum vitamin K concentrations in patients who have fractures are lower than in normal subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The percentage of non-carboxylated osteocalcin in the serum of elderly women (who have a greater fracture risk) is higher than in young women [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of hip fracture in women with high serum concentrations of non-carboxylated osteocalcin is higher (relative risk 5.9) than in women with low concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Treatment of postmenopausal women with vitamin K reduces urinary excretion of hydroxyproline, a marker of bone resorption [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical importance of these observations is uncertain. Some cross-sectional studies have found that mean bone density in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -treated patients was lower than in control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], and a retrospective cohort study found that long-term exposure to warfarin was associated with an increased risk of vertebral and rib fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/21\">",
"     21",
"    </a>",
"    ]. Low bone density was also reported in a small case-control study of children on long-term warfarin versus control children [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/22\">",
"     22",
"    </a>",
"    ]. In a retrospective cohort study of hospitalized patients with atrial fibrillation, men, but not women, who had taken warfarin for more than one year were at increased risk for osteoporotic fracture (odds ratio 1.63; 95% CI 1.26-2.10) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in other studies",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    had no adverse effect on bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/24,25\">",
"     24,25",
"    </a>",
"    ] or fracture rates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In a prospective observational study of women aged 65 years and older, for example, those taking warfarin (n = 149) and those not taking it (n = 6052) had similar rates of bone loss at the hip (1.1 and 0.8 percent, respectively) over two years, and similar fracture rates over 3.5 years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We currently do not recommend any specific treatment directed toward bone in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abundant animal data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    adversely affects bone. Administration of cyclosporine to rats, for example, causes an increase in both bone resorption and bone loss, or \"high-turnover\" osteoporosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/28-30\">",
"     28-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is some evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    may increase bone turnover in humans as it does in rats [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. However, the effect of cyclosporine on bone metabolism in humans is less clear, being confounded by the presence of other illnesses or drugs that affect bone, particularly glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=see_link\">",
"     \"Osteoporosis after solid organ or stem cell transplantation\"",
"    </a>",
"    .) As an example, one study evaluated bone mineral density and bone histology in 20 living-related donor renal transplant recipients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , cyclosporine, and low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/31\">",
"     31",
"    </a>",
"    ]. These patients lost 6.8 percent of their initial bone mass during the first six months after transplantation due to a low&ndash;turnover bone disorder resembling that induced by glucocorticoids. By 18 months, bone density had decreased 9.0 percent from baseline, and 60 percent of the patients had bone mineral density values below the fracture threshold. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=see_link\">",
"     \"Parathyroid and mineral metabolism after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, another randomized study compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    with placebo in patients with primary biliary cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/32\">",
"     32",
"    </a>",
"    ]. Patients receiving cyclosporine had evidence of increased bone turnover; however, cyclosporine decreased the bone loss that normally occurs in this disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29830?source=see_link\">",
"     \"Metabolic bone disease in primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus bone loss is common in many of the illnesses treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , but the role of cyclosporine alone has not been determined. We currently do not recommend any specific treatment directed toward bone in patients taking cyclosporine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Medroxyprogesterone acetate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The low doses (5 to 10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"     medroxyprogesterone acetate",
"    </a>",
"    (MPA, Provera) that are typically used in combination with estrogen as part of a regimen of postmenopausal hormone therapy have no effect on the ability of estrogen to prevent bone loss. This issue was best addressed in the Postmenopausal",
"    <span class=\"nowrap\">",
"     Estrogen/Progestin",
"    </span>",
"    Interventions (PEPI) Trial in which 875 women were randomly assigned to placebo or one of four treatment arms consisting of conjugated estrogens (0.625",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    alone or with three different progestin regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/33\">",
"     33",
"    </a>",
"    ]. At three years, bone mineral density (BMD) increased similarly in all treatment groups and fell in the placebo group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=see_link\">",
"     \"Postmenopausal hormone therapy in the prevention and treatment of osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, the higher doses of MPA that have been used to treat gynecologic disorders or that have been given for contraception have been associated with increased bone loss, presumably due to the induction of estrogen deficiency. In 2004, the United States Food and Drug Administration (FDA) required additional labeling recommending that DepoMPA (DMPA) be used as a long-term birth control method (eg, longer than two years) only if other birth control methods are inadequate and, if used long-term, BMD should be evaluated. This topic is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=see_link&amp;anchor=H18#H18\">",
"     \"Depot medroxyprogesterone acetate for contraception\", section on 'Reduction in bone mineral density'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Vitamin A and synthetic retinoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin A is required for normal growth, vision, reproduction, cell proliferation, and cell differentiation. However, excess intake appears to increase the risk of hip fracture in women. The mechanism by which this may occur has been studied in animals, in which vitamin A inhibited osteoblast activity, stimulated osteoclast formation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/34\">",
"     34",
"    </a>",
"    ], and counteracted the ability of vitamin D to maintain normal serum calcium concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/35\">",
"     35",
"    </a>",
"    ], thereby leading to accelerated bone resorption and fractures. The data in humans has been conflicting, but at least four studies have found an association between excess vitamin A intake and osteoporotic fracture:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first was a nested case-control study in Sweden, where both vitamin A intake and the incidence of hip fracture are high [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/36\">",
"       36",
"      </a>",
"      ]. In this report, there was a 10 percent reduction in femoral bone mineral density and a doubling in the risk of hip fracture (odds ratio 2.1, 95% CI 1.1-4.0) among women who consumed more than 1500 mcg retinol per day compared with women who consumed less than 500 mcg per day. The risk was graded; for every 1 mg increase in daily retinol intake, the risk for hip fracture increased by 68 percent (95% CI 18 to 140 percent).",
"     </li>",
"     <li>",
"      The same group in Sweden reported similar findings in men. In a prospective cohort study of 2322 men followed for up to 30 years, the risk of any fracture or hip fracture was increased in those whose serum retinol concentrations were in the highest quintile as compared with the middle quintile (RR 1.6, 95% CI 1.1-2.4 and 2.5, 95% CI 1.1-5.3, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective analysis from the Nurses' Health Study, 603 women had incident hip fractures resulting from low or moderate trauma during 18 years of study [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/38\">",
"       38",
"      </a>",
"      ]. After controlling for confounding factors, women in the highest quintile of vitamin A intake (&ge;3000",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      of retinol equivalents) had an increased risk of hip fracture (relative risk 1.48, 95% CI 1.05-2.07) compared with women in the lowest quintile of intake (&lt;1250",
"      <span class=\"nowrap\">",
"       mcg/day",
"      </span>",
"      of retinol equivalents). The association between high vitamin A intake and hip fracture was not seen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/50/21283?source=see_link\">",
"       beta-carotene",
"      </a>",
"      intake and was attenuated in women taking postmenopausal hormone therapy.",
"     </li>",
"     <li>",
"      In the Rancho Bernardo Study, a community-based cohort study of elderly men and women, both low and high vitamin A intakes were associated with a lower bone mineral density. Bone density was optimal when vitamin A intake was 2000 to 2800 int. units per day (0.6 to 0.9",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The subjects in these studies were predominantly white and results may not be generalizable to the entire population.",
"   </p>",
"   <p>",
"    Not all studies find a relationship between vitamin A intake and bone loss. In an analysis from the NHANES study, high serum retinyl ester concentrations (a marker of vitamin A intake) were not associated with a decrease in bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/40\">",
"     40",
"    </a>",
"    ]. Similarly, a case control study of patients with incident osteoporotic fractures, serum indices of vitamin A exposure were not predictive of hip fracture or of lower bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the available bone density and fracture data, both men and women in Western countries should be cautioned against excessive vitamin A intake. Common food sources of vitamin A include liver, milk, egg yolk, butter, and some fruits and vegetables; those with diets high in these foods should avoid supplements containing vitamin A. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of vitamin A\", section on 'Requirements'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On the other hand, vitamin A deficiency is still fairly common in African and Asian countries, and inadequate vitamin A intake may also increase fracture risk [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/42\">",
"     42",
"    </a>",
"    ]. For populations in which vitamin A deficiency is endemic, supplementation is recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of vitamin A\", section on 'Deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Loop diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Loop diuretics increase calcium loss by impairing reabsorption in the loop of Henle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link&amp;anchor=H2#H2\">",
"     \"Diuretics and calcium balance\", section on 'Loop of Henle and loop diuretics'",
"    </a>",
"    .) The ensuing negative calcium balance has been associated with a decrease in bone mineral density (BMD) and an increase in risk of hip fracture in some [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/43-45\">",
"     43-45",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/46\">",
"     46",
"    </a>",
"    ], studies. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a clinical trial of 87 healthy, postmenopausal women randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/9/43158?source=see_link\">",
"       bumetanide",
"      </a>",
"      , a loop diuretic, or placebo for one year, urinary calcium and serum PTH increased (17 and 9 percent, respectively), and bone mineral density decreased at the hip (-2 percent) and whole body (-1.4 percent) in the treatment group compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/43\">",
"       43",
"      </a>",
"      ]. This detrimental effect on bone occurred despite supplementation with calcium and vitamin D.",
"     </li>",
"     <li>",
"      In a cohort study of 3269 men, the use of loop diuretics was also associated with a greater decline in total hip BMD compared with nonusers (annual rate of decline -0.78 versus -0.33 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a case-control study, the adjusted relative risk for hip fracture was 3.9 (95% CI 1.5-10.4) in patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      compared with patients not taking furosemide [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in the Women's Health Initiative observational study, there were no significant associations between use of loop diuretics and changes in BMD, falls, and fractures (HR for hip fractures in users versus never users 1.21, 95% CI 0.91-1.60) in models adjusted for confounding variables [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/46\">",
"       46",
"      </a>",
"      ]. Women who used loop diuretics were in poorer health and had more risk factors for fracture than never users. However, one-third of loop diuretic users were taking hormone therapy, and mean calcium intake was 1000 mg daily, interventions that may have decreased fracture incidence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of loop diuretics is in contrast to that of thiazide diuretics, which reduce calcium excretion and may increase bone mineral density. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Thiazide diuretics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chemotherapeutic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of osteoporosis in patients treated for cancer are due to either the hypogonadism that results from chemotherapy and radiation therapy, from blockade of estrogen synthesis with aromatase inhibitors, or to glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=see_link\">",
"     \"Ovarian failure due to anticancer drugs and radiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37545?source=see_link\">",
"     \"Evaluation and management of aromatase inhibitor-induced bone loss\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, direct negative skeletal effects have been described for certain chemotherapeutic drugs:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    regimens (such as those used for osteosarcoma or acute lymphoblastic leukemia) are associated with an increase in bone resorption and an inhibition of bone formation, resulting in both osteoporosis and fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Ifosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     Ifosfamide",
"    </a>",
"    can damage the proximal tubules, causing metabolic acidosis, renal phosphate loss, hypercalciuria and, in severe cases, hypophosphatemic osteomalacia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14806?source=see_link\">",
"     \"Ifosfamide nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Imatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/1/17434?source=see_link\">",
"     Imatinib",
"    </a>",
"    mesylate, a drug used in the treatment of chronic myeloid leukemia, gastrointestinal stromal tumors, and other malignancies, may be associated with changes in bone turnover [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. In one preliminary report, patients receiving imatinib had increases in markers of bone formation (serum osteocalcin and P1NP) but no change in a marker of bone resorption (beta isomer of C-terminal telopeptide of type I collagen) within three months of initiating therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/50\">",
"     50",
"    </a>",
"    ]. In some instances, changes in bone turnover were associated with low-normal serum calcium, secondary hyperparathyroidism, renal phosphate wasting, and hypophosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The mechanism and clinical consequences of these findings are unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link\">",
"     \"Causes of hypophosphatemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Antiepileptic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many antiepileptic drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ) increase the activity of P-450 enzymes. Induction of the cytochrome P450 system by AEDs leads to increased catabolism of vitamin D to inactive metabolites and a subsequent rise in parathyroid hormone, which increases the mobilization of bone calcium stores and subsequent bone turnover. In ambulatory patients, long-term antiepileptic therapy has been associated with low bone density and an increase in fractures. The increase in fracture rate is due to both seizure-related injuries and the adverse effects of AEDs on bone strength. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36969?source=see_link\">",
"     \"Antiepileptic drugs and bone disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insoluble calcium, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    , requires an acid environment for optimal absorption. As a result, drugs that reduce stomach acid secretion (proton pump inhibitors [PPIs] and H2 blockers) may reduce calcium absorption. Because calcium absorption decreases with aging, a further reduction in calcium absorption with the addition of such drugs may have an adverse impact on skeletal health, particularly in elderly individuals.",
"   </p>",
"   <p>",
"    Some [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/51\">",
"     51",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/52\">",
"     52",
"    </a>",
"    ], studies with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    showed that fractional absorption of calcium was reduced in postmenopausal women. A possible explanation for the different results among studies is a difference in study conditions, including selection of isotope-labelled calcium (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    capsules versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15799?source=see_link\">",
"     calcium chloride",
"    </a>",
"    solution), method of measurement (fasting serum isotope-labelled calcium levels versus dual isotope measurements with a meal), duration of omeprazole treatment (7 versus 30 days), and patient characteristics (mean age 76 versus 58 years). Dietary calcium (milk and cheese) absorption was not reduced in healthy individuals treated with omeprazole [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/53,54\">",
"     53,54",
"    </a>",
"    ], suggesting that a meal induces a sufficient amount of acid secretion for calcium absorption despite PPI therapy.",
"   </p>",
"   <p>",
"    The more important clinical question is whether PPIs affect fracture risk. In meta-analyses of case-control and cohort studies, the risk of hip, spine, and any-site fractures was modestly but significantly increased in patients taking proton pump inhibitors (RRs 1.30, 1.56, and 1.16, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/55-58\">",
"     55-58",
"    </a>",
"    ]. In some studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/57,59\">",
"     57,59",
"    </a>",
"    ], but not another [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/60\">",
"     60",
"    </a>",
"    ], the risk was highest in long-term users of high dose PPI therapy. In one analysis, the risk was confined to patients with at least one other risk factor for hip fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/61\">",
"     61",
"    </a>",
"    ], and in another, to current or former smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest prospective cohort study (the Women's Health Initiative [WHI] Study) did not find an association between PPI use and hip fracture (HR 1.00, 95% CI 0.71-1.40) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/62\">",
"     62",
"    </a>",
"    ]. However, PPI use was associated with an increased risk of clinical vertebral (HR 1.47, 95% CI 1.18-1.82), wrist, and total fractures. However, there was a smaller number of hip fracture events compared with wrist, clinical spine, or total fractures. The lower number of events, combined with the fact that PPI users were more likely than nonusers to be taking hormone therapy, may have reduced the ability of the study to detect an increased risk of hip fracture in PPI users.",
"   </p>",
"   <p>",
"    H2 blockers were associated with an increased risk of hip fracture in some reports (AOR 1.23, 95% CI 1.14-1.39) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/59,61,63\">",
"     59,61,63",
"    </a>",
"    ], but decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/60\">",
"     60",
"    </a>",
"    ], or unchanged [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/58,62\">",
"     58,62",
"    </a>",
"    ] in others.",
"   </p>",
"   <p>",
"    In a subsequent analysis of a national prescription database, concurrent use of PPIs and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    compared with alendronate alone was associated with loss of protection against hip fracture (fracture risk reduction with alendronate 39 versus 19 percent in non-PPI versus PPI users) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/64\">",
"     64",
"    </a>",
"    ]. Concurrent treatment with H2 blockers did not modify the treatment response to alendronate.",
"   </p>",
"   <p>",
"    Although the association between PPIs and fracture is plausible, these observational studies do not prove causality. One possible mechanism by which PPIs and H2 blockers adversely affect bone is through impaired absorption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    due to achlorhydria, which increases bone loss and reduces bone mineral density (BMD). In a prospective cohort study, chronic PPI use was associated with lower baseline BMD at the femoral neck and total hip, but use over 10 years was not associated with accelerated BMD decline [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/65\">",
"     65",
"    </a>",
"    ]. As a result, factors independent of BMD (eg, frailty) may contribute to fracture risk, and further studies investigating the relationship between PPIs and fracture are required.",
"   </p>",
"   <p>",
"    In the interim, because",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    was shown to reduce the fractional absorption of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/32/42504?source=see_link\">",
"     calcium carbonate",
"    </a>",
"    in fasting postmenopausal women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/51\">",
"     51",
"    </a>",
"    ], we recommend that postmenopausal women taking long-term PPI or H2 blocker therapy increase dietary calcium and, when necessary, use calcium supplements that do not require acid for absorption, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"     calcium citrate",
"    </a>",
"    . The treatment of postmenopausal women with or at risk for osteoporotic fracture is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link&amp;anchor=H10#H10\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Supplements'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Pharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Antidepressants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs) have been associated with an increased risk of fragility fracture in observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/66-68\">",
"     66-68",
"    </a>",
"    ]. A meta-analysis of 12 case-control and cohort studies showed an increased risk of fracture (predominantly hip and nonvertebral fracture) in patients who had taken an SSRI (RR 1.72, 95% CI 1.51-1.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/69\">",
"     69",
"    </a>",
"    ]. The increased risk persisted after confining the analysis to studies that adjusted for important risk factors for fracture (age, comorbidities, medications known to increase fracture risk, bone mineral density).",
"   </p>",
"   <p>",
"    The results from these studies do not prove causality and other confounders not controlled for during statistical analysis may explain the observed association. However, one mechanism to explain the possible association between antidepressants and fracture is the adverse effects of the drugs, including sedation and postural hypotension, which may increase risk of falls. Nevertheless, in some large cross-sectional and prospective cohort studies, use of selective serotonin reuptake inhibitors (SSRIs), but not tricyclic antidepressants (TCAs), has been associated with reduced bone mineral density in elderly men [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/70\">",
"     70",
"    </a>",
"    ] and increased rates of bone loss at the hip in elderly women [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/71\">",
"     71",
"    </a>",
"    ]. Thus, an alternative possibility is a direct effect of SSRIs on bone metabolism, although studies in this regard are preliminary [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prospective trials are needed to definitively determine the relationship between antidepressants and fracture. In the interim, we recommend that the risks of potential fracture be balanced against the benefits gained from treating depression, especially in elderly persons who are already at increased risk for osteoporosis and fracture. The decision to prescribe SSRIs versus TCAs should not be driven by fracture data, since there is only observational data that either may increase risk of fracture.",
"   </p>",
"   <p>",
"    We also recommend counseling regarding fall prevention, adequate calcium and vitamin D supplementation, and smoking cessation, which are important lifestyle changes that may prevent fracture. Bone mineral density testing should be considered in patients receiving SSRIs, especially when other risk factors for fracture are present, such as advanced age or prior history of fragility fracture. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"     \"Osteoporotic fracture risk assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention of osteoporosis\", section on 'Nonpharmacologic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Thiazolidinediones",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence suggesting that thiazolidinediones have an adverse impact on skeletal health, including an increased risk of fractures in women (humerus, hand, foot). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=see_link&amp;anchor=H18#H18\">",
"     \"Thiazolidinediones in the treatment of diabetes mellitus\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Antiretroviral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased risk of reduced bone density in HIV-infected individuals. Low BMD among patients with HIV infection is usually multifactorial. This topic is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=see_link&amp;anchor=H4#H4\">",
"     \"Bone and calcium disorders in HIV-infected patients\", section on 'Effects of medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DRUGS THAT MAY HAVE BENEFICIAL EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Thiazide diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thiazide diuretics stimulate distal tubular reabsorption of calcium, leading to a decrease in urinary calcium excretion. This effect is used clinically to reduce the frequency of stone formation in patients with recurrent nephrolithiasis and hypercalciuria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link\">",
"     \"Diuretics and calcium balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, thiazide diuretics may have a beneficial effect on bone mineral density. This is in contrast to loop diuretics, which increase calcium excretion and may reduce bone mineral density. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Loop diuretics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Bone mineral density",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term thiazide therapy may increase bone density and decrease fracture risk. In cross-sectional studies, patients taking a thiazide had a higher bone density than control patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. A report of 9704 white women, for example, found that the forearm and calcaneus density was 4 to 5 percent higher in those taking a thiazide, even after correcting for other confounding variables such as body mass index and calcium intake [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are also clinical trial data that demonstrate a beneficial effect of thiazide diuretics on bone mineral density:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a controlled trial of 184 normal postmenopausal women,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for two years) resulted in a significant increase in forearm but not lumbar spine or hip density [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A three-year trial of 320 normal men and women aged 60 to 79 years examined the effect of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8263?source=see_link\">",
"       hydrochlorothiazide",
"      </a>",
"      (12.5 or 25",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      versus placebo. In women, the hip and spine density was 1.4 and 1.3 percent higher, respectively, in the 25 mg-group compared with the placebo group [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/76\">",
"       76",
"      </a>",
"      ]; the effect of the 12.5 mg dose was smaller. Hydrochlorothiazide also prevented bone loss in men, although the effect was less than in women (0.7 and 0.4 percent versus placebo in the hip and spine, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/76\">",
"       76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Fracture risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/73,77-81\">",
"     73,77-81",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/45\">",
"     45",
"    </a>",
"    ], observational studies have shown a beneficial effect of thiazides on fracture risk. A 1995 meta-analysis of 13 observational studies involving almost 30,000 subjects noted that the hip fracture risk was significantly reduced by 18 percent with long-term thiazide therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/81\">",
"     81",
"    </a>",
"    ]. A greater benefit was noted in a prospective cohort study published after the meta-analysis of almost 8000 individuals (hazard ratio 0.46 with current use of a thiazide for more than one year compared to nonuse) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/78\">",
"     78",
"    </a>",
"    ]. This benefit disappeared four months after thiazide therapy was discontinued.",
"   </p>",
"   <p>",
"    Although a randomized clinical trial has not been performed, we conclude that thiazide therapy attenuates bone loss, and may reduce fracture risk, but the effect is modest. We do not routinely recommend the administration of thiazides to prevent or treat osteoporosis, but a thiazide diuretic is a reasonable choice if a patient with osteoporosis has hypertension or nephrolithiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been thought that HMG CoA reductase inhibitors (statins), which are used for the treatment of hypercholesterolemia, may have beneficial effects on the skeleton, but data are conflicting. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10230?source=see_link\">",
"     \"Statins: Possible noncardiovascular benefits\"",
"    </a>",
"    .) In some studies, statin therapy was associated with a decrease in fractures or an increase in bone density [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/82-86\">",
"     82-86",
"    </a>",
"    ], but in others there was no decrease in fractures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]. Many of the studies included men, sometimes in a majority, the particular statin varied, and the design of the studies varied. Most were case-control or retrospective studies.",
"   </p>",
"   <p>",
"    The Women's Health Initiative Observational Study, the largest observational study to address this issue, reported no reduction in fracture rates in postmenopausal statin users compared to nonusers after four years of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/90\">",
"     90",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a meta-analysis of eight observational studies that reported statin use and documented fracture outcomes in postmenopausal women (including the WHI observational study noted above), statin use was associated with a lower risk of hip fracture (odds ratio 0.43, 95% CI 0.25-0.75 for users versus nonusers) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/91\">",
"     91",
"    </a>",
"    ]. However, post hoc analyses of two cardiovascular trials did not support a protective effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/87,89\">",
"     87,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the one clinical trial to date, 82 postmenopausal women were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    (40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo for one year. There were no effects of simvastatin on biochemical bone markers or on bone mineral density at the hip or spine, although an increase in bone density was seen in the forearm. Thus, observational data on statin use and beneficial effects on bone health have been conflicting, but in the one randomized clinical trial to address this, simvastatin did not appear to have an overall beneficial effect on bone [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide slows bone remodeling and bone loss in animals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/93\">",
"     93",
"    </a>",
"    ]. In observational studies in humans, nitrate administration, which increases nitric oxide levels, was associated with an increase in bone mineral density [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/94\">",
"     94",
"    </a>",
"    ] and a reduction in fracture risk [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    on bone density are illustrated by the results of the following randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a three-year trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      ointment (22.5",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      versus placebo in 186 postmenopausal women without osteoporosis (BMD T-scores between 0 and -2.5 and no prior vertebral or hip fracture), there were similar reductions in lumbar spine and total hip BMD after 36 months (-2.06 versus -2.48 percent and -4.38 versus -4.03 percent for lumbar spine and total hip, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a two-year trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      ointment (15",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      versus placebo in 243 postmenopausal women with BMD T-scores between 0 and -2.0, there were significant increases in lumbar spine and total hip BMD in the nitroglycerin group (8.6 versus 1.9 percent and 5.4 versus -1.1 percent for lumbar spine and total hip, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neither of the trials was powered to assess fracture outcomes. The differences in the results reported may be related to study design and compliance with the study medication. Headaches were a common side effect in both trials, occurring in 35 to 57 percent of women in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    group. In one trial, compliance (70 percent) with nitroglycerin ointment was lower than expected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    ointment for the treatment of osteoporosis. However, postmenopausal women who use nitroglycerin ointment daily for the treatment of chronic stable angina may have a reduced risk of osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;In animal models, beta blockers stimulate bone formation and inhibit bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/98\">",
"     98",
"    </a>",
"    ]. Data in humans are inconsistent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a case-control study of women taking beta blockers (569 with fracture and 775 controls without a fracture) beta blocker use was associated with a lower fracture risk (odds ratio 0.68, 95% CI 0.49-0.96) and a higher BMD (2.5 percent increase in hip BMD after controlling for confounders) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/99\">",
"       99",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a large, population-based, case-control analysis of 30,601 subjects 30 to 79 years of age with a fracture and 120,819 controls without fracture, the current use of beta blockers, thiazide diuretics, or both was associated with a lower risk of fracture when compared with non-users (OR 0.77, 95% CI 0.72-0.83; 0.80, 95% CI 0.74-0.86; and 0.71, 95% CI 0.64-0.79 for beta blockers, thiazides, and combination therapy, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In contrast, in a large prospective cohort study, beta-blocker use was not associated with higher bone mineral density or lower fracture risk when compared to nonusers [",
"      <a class=\"abstract\" href=\"UTD.htm?9/21/9562/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the inconsistent observational data and the absence of clinical trial data, beta blockers have no current role in osteoporosis management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are several drugs that have been associated with a decrease in bone mineral density (BMD) and an increase in the risk of fracture, whereas other drugs appear to improve BMD and decrease the risk of fracture. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Drugs that may have adverse effects'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Drugs that may have beneficial effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In observational studies, commonly used medications, such as proton pump inhibitors, antidepressants, anticoagulants, and loop diuretics have been associated with an increased risk of fracture. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Drugs that may have adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When these medications are given for a brief period of time, the adverse skeletal effects are of less concern. Because long-term therapy may have detrimental skeletal effects, older patients should be evaluated for other risk factors for osteoporosis and fracture and counseled regarding fall prevention, adequate calcium and vitamin D supplementation, and smoking cessation, which are important lifestyle changes that may prevent fracture. Bone mineral density testing should be considered in some patients, especially when other risk factors for fracture are present, such as advanced age or prior history of fragility fracture. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=see_link\">",
"       \"Osteoporotic fracture risk assessment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link&amp;anchor=H13#H13\">",
"       \"Screening for osteoporosis\", section on 'Candidates for BMD testing'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"       \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"       \"Treatment of osteoporosis in men\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The skeletal effects of glucocorticoids are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/1\">",
"      Wolinsky-Friedland M. Drug-induced metabolic bone disease. Endocrinol Metab Clin North Am 1995; 24:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/2\">",
"      Pitts CJ, Kearns AE. Update on medications with adverse skeletal effects. Mayo Clin Proc 2011; 86:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/3\">",
"      van der Wiel HE, Lips P, Huijgens PC, Netelenbos JC. Effects of short-term low-dose heparin administration on biochemical parameters of bone turnover. Bone Miner 1993; 22:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/4\">",
"      Muir JM, Andrew M, Hirsh J, et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 1996; 88:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/5\">",
"      Hirsh J. Oral anticoagulant drugs. N Engl J Med 1991; 324:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/6\">",
"      Barbour LA, Kick SD, Steiner JF, et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994; 170:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/7\">",
"      Dahlman TC, Sj&ouml;berg HE, Ringertz H. Bone mineral density during long-term prophylaxis with heparin in pregnancy. Am J Obstet Gynecol 1994; 170:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/8\">",
"      Dahlman T, Lindvall N, Hellgren M. Osteopenia in pregnancy during long-term heparin treatment: a radiological study post partum. Br J Obstet Gynaecol 1990; 97:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/9\">",
"      Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/10\">",
"      Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/11\">",
"      Pettil&auml; V, Leinonen P, Markkola A, et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/12\">",
"      Backos M, Rai R, Thomas E, et al. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod 1999; 14:2876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/13\">",
"      Lian JB, Gundberg CM. Osteocalcin. Biochemical considerations and clinical applications. Clin Orthop Relat Res 1988; :267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/14\">",
"      Hodges SJ, Akesson K, Vergnaud P, et al. Circulating levels of vitamins K1 and K2 decreased in elderly women with hip fracture. J Bone Miner Res 1993; 8:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/15\">",
"      Bitensky L, Hart JP, Catterall A, et al. Circulating vitamin K levels in patients with fractures. J Bone Joint Surg Br 1988; 70:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/16\">",
"      Plantalech L, Guillaumont M, Vergnaud P, et al. Impairment of gamma carboxylation of circulating osteocalcin (bone gla protein) in elderly women. J Bone Miner Res 1991; 6:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/17\">",
"      Szulc P, Chapuy MC, Meunier PJ, Delmas PD. Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J Clin Invest 1993; 91:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/18\">",
"      Knapen MH, Hamuly&aacute;k K, Vermeer C. The effect of vitamin K supplementation on circulating osteocalcin (bone Gla protein) and urinary calcium excretion. Ann Intern Med 1989; 111:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/19\">",
"      Fiore CE, Tamburino C, Foti R, Grimaldi D. Reduced axial bone mineral content in patients taking an oral anticoagulant. South Med J 1990; 83:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/20\">",
"      Philip WJ, Martin JC, Richardson JM, et al. Decreased axial and peripheral bone density in patients taking long-term warfarin. QJM 1995; 88:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/21\">",
"      Caraballo PJ, Heit JA, Atkinson EJ, et al. Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med 1999; 159:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/22\">",
"      Barnes C, Newall F, Ignjatovic V, et al. Reduced bone density in children on long-term warfarin. Pediatr Res 2005; 57:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/23\">",
"      Gage BF, Birman-Deych E, Radford MJ, et al. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 2006; 166:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/24\">",
"      Piro LD, Whyte MP, Murphy WA, Birge SJ. Normal cortical bone mass in patients after long term coumadin therapy. J Clin Endocrinol Metab 1982; 54:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/25\">",
"      Rosen HN, Maitland LA, Suttie JW, et al. Vitamin K and maintenance of skeletal integrity in adults. Am J Med 1993; 94:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/26\">",
"      Jamal SA, Browner WS, Bauer DC, Cummings SR. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998; 128:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/27\">",
"      Woo C, Chang LL, Ewing SK, et al. Single-point assessment of warfarin use and risk of osteoporosis in elderly men. J Am Geriatr Soc 2008; 56:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/28\">",
"      Bryer HP, Isserow JA, Armstrong EC, et al. Azathioprine alone is bone sparing and does not alter cyclosporin A-induced osteopenia in the rat. J Bone Miner Res 1995; 10:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/29\">",
"      Movsowitz C, Epstein S, Fallon M, et al. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology 1988; 123:2571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/30\">",
"      Mann GN, Jacobs TW, Buchinsky FJ, et al. Interferon-gamma causes loss of bone volume in vivo and fails to ameliorate cyclosporin A-induced osteopenia. Endocrinology 1994; 135:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/31\">",
"      Julian BA, Laskow DA, Dubovsky J, et al. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med 1991; 325:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/32\">",
"      Gua&ntilde;abens N, Par&eacute;s A, Navasa M, et al. Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. J Hepatol 1994; 21:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/33\">",
"      Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. JAMA 1996; 276:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/34\">",
"      Togari A, Kondo M, Arai M, Matsumoto S. Effects of retinoic acid on bone formation and resorption in cultured mouse calvaria. Gen Pharmacol 1991; 22:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/35\">",
"      Rohde CM, Manatt M, Clagett-Dame M, DeLuca HF. Vitamin A antagonizes the action of vitamin D in rats. J Nutr 1999; 129:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/36\">",
"      Melhus H, Micha&euml;lsson K, Kindmark A, et al. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med 1998; 129:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/37\">",
"      Micha&euml;lsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med 2003; 348:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/38\">",
"      Feskanich D, Singh V, Willett WC, Colditz GA. Vitamin A intake and hip fractures among postmenopausal women. JAMA 2002; 287:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/39\">",
"      Promislow JH, Goodman-Gruen D, Slymen DJ, Barrett-Connor E. Retinol intake and bone mineral density in the elderly: the Rancho Bernardo Study. J Bone Miner Res 2002; 17:1349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/40\">",
"      Ballew C, Galuska D, Gillespie C. High serum retinyl esters are not associated with reduced bone mineral density in the Third National Health And Nutrition Examination Survey, 1988-1994. J Bone Miner Res 2001; 16:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/41\">",
"      Barker ME, McCloskey E, Saha S, et al. Serum retinoids and beta-carotene as predictors of hip and other fractures in elderly women. J Bone Miner Res 2005; 20:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/42\">",
"      Opotowsky AR, Bilezikian JP, NHANES I follow-up study. Serum vitamin A concentration and the risk of hip fracture among women 50 to 74 years old in the United States: a prospective analysis of the NHANES I follow-up study. Am J Med 2004; 117:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/43\">",
"      Rejnmark L, Vestergaard P, Heickendorff L, et al. Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res 2006; 21:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/44\">",
"      Lim LS, Fink HA, Kuskowski MA, et al. Loop diuretic use and increased rates of hip bone loss in older men: the Osteoporotic Fractures in Men Study. Arch Intern Med 2008; 168:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/45\">",
"      Heidrich FE, Stergachis A, Gross KM. Diuretic drug use and the risk for hip fracture. Ann Intern Med 1991; 115:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/46\">",
"      Carbone LD, Johnson KC, Bush AJ, et al. Loop diuretic use and fracture in postmenopausal women: findings from the Women's Health Initiative. Arch Intern Med 2009; 169:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/47\">",
"      Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000; 18:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/48\">",
"      Schwartz AM, Leonidas JC. Methotrexate osteopathy. Skeletal Radiol 1984; 11:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/49\">",
"      Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/50\">",
"      Grey A, O'Sullivan S, Reid IR, Browett P. Imatinib mesylate, increased bone formation, and secondary hyperparathyroidism. N Engl J Med 2006; 355:2494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/51\">",
"      O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. Am J Med 2005; 118:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/52\">",
"      Hansen KE, Jones AN, Lindstrom MJ, et al. Do proton pump inhibitors decrease calcium absorption? J Bone Miner Res 2010; 25:2786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/53\">",
"      Serfaty-Lacrosniere C, Wood RJ, Voytko D, et al. Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr 1995; 14:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/54\">",
"      Wright MJ, Sullivan RR, Gaffney-Stomberg E, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: a randomized, crossover, controlled clinical trial. J Bone Miner Res 2010; 25:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/55\">",
"      Yu EW, Bauer SR, Bain PA, Bauer DC. Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies. Am J Med 2011; 124:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/56\">",
"      Ngamruengphong S, Leontiadis GI, Radhi S, et al. Proton pump inhibitors and risk of fracture: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2011; 106:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/57\">",
"      Khalili H, Huang ES, Jacobson BC, et al. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: a prospective cohort study. BMJ 2012; 344:e372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/58\">",
"      Kwok CS, Yeong JK, Loke YK. Meta-analysis: risk of fractures with acid-suppressing medication. Bone 2011; 48:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/59\">",
"      Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296:2947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/60\">",
"      Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006; 79:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/61\">",
"      Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 2010; 139:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/62\">",
"      Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med 2010; 170:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/63\">",
"      de Vries F, Cooper AL, Cockle SM, et al. Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int 2009; 20:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/64\">",
"      Abrahamsen B, Eiken P, Eastell R. Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med 2011; 171:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/65\">",
"      Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012; 107:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/66\">",
"      Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/67\">",
"      Ensrud KE, Blackwell T, Mangione CM, et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003; 163:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/68\">",
"      Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007; 167:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/69\">",
"      Wu Q, Bencaz AF, Hentz JG, Crowell MD. Selective serotonin reuptake inhibitor treatment and risk of fractures: a meta-analysis of cohort and case-control studies. Osteoporos Int 2012; 23:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/70\">",
"      Haney EM, Chan BK, Diem SJ, et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007; 167:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/71\">",
"      Diem SJ, Blackwell TL, Stone KL, et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007; 167:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/72\">",
"      Battaglino R, Fu J, Sp&auml;te U, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 2004; 19:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/73\">",
"      Cauley JA, Cummings SR, Seeley DG, et al. Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1993; 118:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/74\">",
"      Orwoll ES, Bauer DC, Vogt TM, Fox KM. Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1996; 124:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/75\">",
"      Reid IR, Ames RW, Orr-Walker BJ, et al. Hydrochlorothiazide reduces loss of cortical bone in normal postmenopausal women: a randomized controlled trial. Am J Med 2000; 109:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/76\">",
"      LaCroix AZ, Ott SM, Ichikawa L, et al. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2000; 133:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/77\">",
"      Felson DT, Sloutskis D, Anderson JJ, et al. Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study. JAMA 1991; 265:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/78\">",
"      Schoofs MW, van der Klift M, Hofman A, et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003; 139:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/79\">",
"      LaCroix AZ, Wienpahl J, White LR, et al. Thiazide diuretic agents and the incidence of hip fracture. N Engl J Med 1990; 322:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/80\">",
"      Ray, WA, Griffin, MR, Downey, W, Melton JLI. Long-term use of thiazide diuretics and risk of hip fracture. Lancet 1989; 1:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/81\">",
"      Jones G, Nguyen T, Sambrook PN, Eisman JA. Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res 1995; 10:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/82\">",
"      Wang PS, Solomon DH, Mogun H, Avorn J. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000; 283:3211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/83\">",
"      Chung YS, Lee MD, Lee SK, et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000; 85:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/84\">",
"      Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355:2185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/85\">",
"      Pasco JA, Kotowicz MA, Henry MJ, et al. Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 2002; 162:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/86\">",
"      Scranton RE, Young M, Lawler E, et al. Statin use and fracture risk: study of a US veterans population. Arch Intern Med 2005; 165:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/87\">",
"      Pedersen TR, Kjekshus J. Statin drugs and the risk of fracture. 4S Study Group. JAMA 2000; 284:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/88\">",
"      van Staa TP, Wegman S, de Vries F, et al. Use of statins and risk of fractures. JAMA 2001; 285:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/89\">",
"      Reid IR, Hague W, Emberson J, et al. Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 2001; 357:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/90\">",
"      LaCroix AZ, Cauley JA, Pettinger M, et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 2003; 139:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/91\">",
"      Bauer DC, Mundy GR, Jamal SA, et al. Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 2004; 164:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/92\">",
"      Rejnmark L, Buus NH, Vestergaard P, et al. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 2004; 19:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/93\">",
"      Wimalawansa SJ, De Marco G, Gangula P, Yallampalli C. Nitric oxide donor alleviates ovariectomy-induced bone loss. Bone 1996; 18:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/94\">",
"      Jamal SA, Browner WS, Bauer DC, Cummings SR. Intermittent use of nitrates increases bone mineral density: the study of osteoporotic fractures. J Bone Miner Res 1998; 13:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/95\">",
"      Rejnmark L, Vestergaard P, Mosekilde L. Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res 2006; 21:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/96\">",
"      Wimalawansa SJ, Grimes JP, Wilson AC, Hoover DR. Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss. J Clin Endocrinol Metab 2009; 94:3356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/97\">",
"      Jamal SA, Hamilton CJ, Eastell R, Cummings SR. Effect of nitroglycerin ointment on bone density and strength in postmenopausal women: a randomized trial. JAMA 2011; 305:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/98\">",
"      Cherruau M, Facchinetti P, Baroukh B, Saffar JL. Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone 1999; 25:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/99\">",
"      Pasco JA, Henry MJ, Sanders KM, et al. Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res 2004; 19:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/100\">",
"      Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA 2004; 292:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/21/9562/abstract/101\">",
"      Reid IR, Gamble GD, Grey AB, et al. beta-Blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005; 20:613.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2036 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9562=[""].join("\n");
var outline_f9_21_9562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DRUGS THAT MAY HAVE ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anticoagulants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Medroxyprogesterone acetate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Vitamin A and synthetic retinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Loop diuretics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chemotherapeutic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Ifosfamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Imatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Antidepressants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Thiazolidinediones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DRUGS THAT MAY HAVE BENEFICIAL EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Thiazide diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Bone mineral density",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Fracture risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Nitrates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/6/36969?source=related_link\">",
"      Antiepileptic drugs and bone disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=related_link\">",
"      Bone and calcium disorders in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=related_link\">",
"      Bone disease with hyperthyroidism and thyroid hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/45/34522?source=related_link\">",
"      Depot medroxyprogesterone acetate for contraception",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/42/37545?source=related_link\">",
"      Evaluation and management of aromatase inhibitor-induced bone loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14806?source=related_link\">",
"      Ifosfamide nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29830?source=related_link\">",
"      Metabolic bone disease in primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29561?source=related_link\">",
"      Osteoporosis after solid organ or stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1447?source=related_link\">",
"      Ovarian failure due to anticancer drugs and radiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21736?source=related_link\">",
"      Overview of vitamin A",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40073?source=related_link\">",
"      Parathyroid and mineral metabolism after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=related_link\">",
"      Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/21/33113?source=related_link\">",
"      Prevention of osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10230?source=related_link\">",
"      Statins: Possible noncardiovascular benefits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/50/21290?source=related_link\">",
"      Thiazolidinediones in the treatment of diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=related_link\">",
"      Vitamin K and the synthesis of gamma carboxyglutamic acid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_21_9563="Diff dx localized myalgia";
var content_f9_21_9563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61398&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis and distinguishing features of localized myalgia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Diagnosis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Distinguishing features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Unusually strenuous exercise or overuse",
"      </td>",
"      <td>",
"       History",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Trauma",
"      </td>",
"      <td>",
"       History, hematoma, ecchymosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pyomyositis",
"      </td>",
"      <td>",
"       Localized erythema, swelling, fever",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Myofascial pain syndrome",
"      </td>",
"      <td>",
"       Trigger points",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Muscle infarction",
"      </td>",
"      <td>",
"       Severe pain without inflammatory findings, often in a patient with diabetes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Compartment syndrome",
"      </td>",
"      <td>",
"       Severe pain without inflammatory findings, often in a patient with recent trauma",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9563=[""].join("\n");
var outline_f9_21_9563=null;
var title_f9_21_9564="Etiologies painful ejaculation";
var content_f9_21_9564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Etiologies of painful ejaculation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urethritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epididymitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Orchitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Abdominal abscess",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penile prosthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bladder cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intra-abdominal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prostate cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inguinal hernia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vesical calculi",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Benign prostatic hyperplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urethral stricture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pelvic musculature spasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Surgical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radical prostatectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transurethral resection of the prostate (TURP)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasectomy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hernia repair",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Medications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tricyclic antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Selective serotonin re-uptake inhibitors (SSRIs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monoaminoxidase inhibitors (MAOIs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Antipsychotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Psychogenic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychiatric",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9564=[""].join("\n");
var outline_f9_21_9564=null;
var title_f9_21_9565="Neuroblastoma risk categories";
var content_f9_21_9565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Children's Oncology Group risk assignment strata",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        INSS Stage",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        MYCN Status",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathology Classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        DNA Ploidy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk Group Assignment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0-21y",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        2",
"       </td>",
"       <td>",
"        &lt;365 d",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;365d-21y",
"       </td>",
"       <td>",
"        Non-Amp",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;365d-21y",
"       </td>",
"       <td>",
"        Amp",
"       </td>",
"       <td>",
"        Favorable",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;365d-21y",
"       </td>",
"       <td>",
"        Amp",
"       </td>",
"       <td>",
"        Unfavorable",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        3",
"       </td>",
"       <td>",
"        &lt;365 d",
"       </td>",
"       <td>",
"        Non-Amp",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;365 d",
"       </td>",
"       <td>",
"        Amp",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;365d-21y",
"       </td>",
"       <td>",
"        Non-Amp",
"       </td>",
"       <td>",
"        Favorable",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;365d-21y",
"       </td>",
"       <td>",
"        Non-Amp",
"       </td>",
"       <td>",
"        Unfavorable",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;365d-21y",
"       </td>",
"       <td>",
"        Amp",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        4",
"       </td>",
"       <td>",
"        &lt;365 d",
"       </td>",
"       <td>",
"        Non-Amp",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;365 d",
"       </td>",
"       <td>",
"        Amp",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;365d-21y",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        _",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"4\">",
"        4S",
"       </td>",
"       <td>",
"        &lt;365 d",
"       </td>",
"       <td>",
"        Non-Amp",
"       </td>",
"       <td>",
"        Favorable",
"       </td>",
"       <td>",
"        &gt; 1",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;365 d",
"       </td>",
"       <td>",
"        Non-Amp",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        = 1",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;365 d",
"       </td>",
"       <td>",
"        Non-Amp",
"       </td>",
"       <td>",
"        Unfavorable",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;365 d",
"       </td>",
"       <td>",
"        Amp",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9565=[""].join("\n");
var outline_f9_21_9565=null;
var title_f9_21_9566="Core components rehab A";
var content_f9_21_9566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Core components of cardiac rehabilitation/secondary prevention programs: Patient assessment, nutritional counseling, and weight management",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Patient assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Medical history: Review current and prior cardiovascular medical and surgical diagnoses and procedures (including assessment of left ventricular function); comorbidities (including peripheral arterial disease, cerebral vascular disease, pulmonary disease, kidney disease, diabetes mellitus, musculoskeletal and neuromuscular disorders, depression, and other pertinent diseases); symptoms of cardiovascular disease; medications (including dose, frequency, and compliance); date of most recent influenza vaccination; cardiovascular risk profile; and educational barriers and preferences. Refer to each core component of care for relevant assessment measures.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Physical examination: Assess cardiopulmonary systems (including pulse rate and regularity, blood pressure, auscultation of heart and lungs, palpation and inspection of lower extremities for edema and presence of arterial pulses); post-cardiovascular procedure wound sites; orthopedic and neuromuscular status; and cognitive function. Refer to each core component for respective additional physical measures.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Testing: Obtain resting 12-lead ECG; assess patient's perceived health-related quality of life or health status. Refer to each core component for additional specified tests.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Document the patient assessment information that reflects the patient's current status and guides the development and implementation of (1) a patient treatment plan that prioritizes goals and outlines intervention strategies for risk reduction, and (2) a discharge/follow-up plan that reflects progress toward goals and guides long-term secondary prevention plans.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Interactively, communicate the treatment and follow-up plans with the patient and appropriate family members/domestic partners in collaboration with the primary healthcare provider.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        In concert with the primary care provider and/or cardiologist, ensure that the patient is taking appropriate doses of aspirin, clopidogrel,",
"        <sub>",
"         &beta;",
"        </sub>",
"        -blockers, lipid-lowering agents, and ACE inhibitors or angiotensin receptor blockers as per the ACC/AHA, and that the patient has had an annual influenza vaccination.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient treatment plan: Documented evidence of patient assessment and priority short-term (ie, weeks-months) goals within the core components of care that guide intervention strategies. Discussion and provision of the initial and follow-up plans to the patient in collaboration with the primary healthcare provider.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Outcome report: Documented evidence of patient outcomes within the core components of care that reflects progress toward goals, including whether the patient is taking appropriate doses of aspirin, clopidogrel,",
"        <sub>",
"         &beta;",
"        </sub>",
"        -blockers, and ACE inhibitors or angiotensin receptor blockers as per the ACC/AHA, and whether the patient has had an annual influenza vaccination (and if not, documented evidence for why not), and identifies specific areas that require further intervention and monitoring.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Discharge plan: Documented discharge plan summarizing long-term goals and strategies for success.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nutritional counseling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obtain estimates of total daily caloric intake and dietary content of saturated fat, trans fat, cholesterol, sodium, and nutrients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assess eating habits, including fruit and vegetable, whole grain, and fish consumption; number of meals and snacks; frequency of dining out; and alcohol consumption.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Determine target areas for nutrition intervention as outlined in the core components of weight, hypertension, diabetes, as well as heart failure, kidney disease, and other comorbidities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prescribe specific dietary modifications aiming to at least attain the saturated fat and cholesterol content limits of the Therapeutic Lifestyle Change diet. Individualize diet plan according to specific target areas as outlined in the core components of weight, hypertension, and diabetes (as outlined in this table), as well as heart failure and other comorbidities. Recommendations should be sensitive and relevant to cultural preferences.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Educate and counsel patient (and appropriate family members/domestic partners) on dietary goals and how to attain them.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Incorporate behavior change models and compliance strategies into counseling sessions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient adheres to prescribed diet.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Patient understands basic principles of dietary content, such as calories, fat, cholesterol, and nutrients.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        A plan has been provided to address eating behavior problems.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Weight management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Measure weight, height, and waist circumference. Calculate body mass index (BMI).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        In patients with BMI &gt;25 kg/m",
"        <sup>",
"         2",
"        </sup>",
"        and/or waist &gt;40 inches in men (102 cm) and &gt;35 inches (88 cm) in women*:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Establish reasonable short-term and long-term weight goals individualized to the patient and his or her associated risk factors (eg, reduce body weight by at least 5 percent and preferably by &gt;10 percent at a rate of 1 to 2 lb/wk over a period of time up to sixmonths).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Develop a combined diet, physical activity/exercise, and behavioral program designed to reduce total caloric intake, maintain appropriate intake of nutrients and fiber, and increase energy expenditure. The exercise component should strive to include daily, longer distance/duration walking (eg, 60 to 90 minutes).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        &bull; Aim for an energy deficit tailored to achieve weight goals (eg, 500 to 1000 kcal/day).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Expected outcomes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Short-term: Continue to assess and modify interventions until progressive weight loss is achieved. Provide referral to specialized, validated nutrition weight loss programs if weight goals are not achieved.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long-term: Patient adheres to diet and physical activity/exercise program aimed toward attainment of established weight goal.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * BMI definitions for overweight and obesity may differ by race/ethnicity and region of the world. Relevant definitions, when available, should be respectively applied.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Balady GJ, Williams MA, Ades PA, et al.&nbsp;Circulation 2007;115:2675. Copyright 2007 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9566=[""].join("\n");
var outline_f9_21_9566=null;
var title_f9_21_9567="Postop CBD stricture stented";
var content_f9_21_9567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cholecystectomy-related stricture treated by stent placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two 10 French stents have been placed side by side. the patient will receive periodic three monthly stent changes for 12 months.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_21_9567=[""].join("\n");
var outline_f9_21_9567=null;
